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REGULATING LIFE AND DEATH: THE CASE
OF ISRAEL'S "HEALTH BASKET"
COMMITTEE
Guy L Seidman*
I. REGULATING MEDICAL CARE - AN INTRODUCTION
There was a time, not so long ago, when government provided few
services (if any) to the general public. The private-public distinction
meant significant autonomy and self-reliance in the private domain, as
the state showed little interest in providing the public services such as
education or medical treatment. As the famous historian A.J.P. Taylor
stated: "Until August 1914 a sensible, law-abiding Englishman could
pass through life and hardly notice the existence of the state, beyond
the post office and the policeman."' This was probably somewhat of
an exaggeration, as by 1914 there were already abundant signs of the
profound change in the concept of government that would mark the
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1. ALAN JOHN PERCIVAL TAYLOR, ENGLISH HISTORY 1914-1915, at 1 (Sir
George Clark ed., Oxford Univ. Press 1965).
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twentieth century. "The state schoolteacher, the national insurance
officer, the labour exchange, the sanitary and factory inspectors, with
their necessary companion the tax collector, were among the outward
and visible signs of this change."2
Historically, medicine, like legal services, was privately funded and
provided. Few could afford to call on a physician, and those who could
were not perceived as hiring the good doctor's services; instead, the
payment would probably be by way of an honorarium, not a fee,
salary, or insurance premium.3 Nineteenth century English doctors
recognized that they were not able to charge the majority of the
population for medical services and the poor "obtained their medical
treatment from collective forms of medical assistance., 4  These
circumstances have changed significantly since the nineteenth century.
2. WILLIAM WADE & CHRISTOPHER FORSYTH, ADMINISTRATIVE LAW 3 (9th
ed. Oxford Univ. Press 2004).
3. See ALBERT R. JONSEN, A SHORT HISTORY OF MEDICAL ETHICS 44
(Oxford Univ. Press 2000). "For centuries, medical fees had been viewed within
the ancient Roman tradition of honoraria: those engaged in the learned
professions . . . were paid with a gift . . . During the Renaissance . . . [p]hyician
writers begin to think of their [payment for compensation] as salarium rather than
honorarium..." Well into twentieth century England, the ratio of medical doctors
to other people was far below current levels: in 1851, the population-per-doctor
ratio was 1 in 1,028. It declined to 1 in 1,396 in 1861; 1 in 1,552 in 1871; and 1 in
1,723 in 1881. It improved to 1 in 1,527 in 1891; 1 in 1439 in 1901; and 1 in 1,539 in
1911 (with 23,469 doctors treating a population of 36,136,000). ANNE DIGBY,
MAKING A MEDICAL LIVING, DOCTORS AND PATIENTS IN THE ENGLISH MARKET
FOR MEDICINE, 1720-1911 tab. 1.1, at 15 (Peter Laslett, Roger Schofield, E. A.
Wrigley & Daniel Scott Smith, eds., Cambridge Univ. Press 1994). The doctors
per thousand ratio has been rising steadily in the United Kingdom, however. In
1993, it was 2.3 doctors per 1000 population (or 1 in 435), but was still well below
the OECD's average of 2.9. This may lead one to wonder whether more
physicians necessarily mean better medicine. Karen Bloor, Vivien Hendry & Alan
Maynard, Do We Need More Doctors?, 99 J. ROYAL SOC. MED. 281, 281 (2006),
available at http://www.rsm.ac.uk/ media/ downloads/ j06-06moredrs.pdf. See
generally STEVEN SIMOENS & JEREMY HURST, ORG. FOR ECON. CO-OPERATION
AND DEV., THE SUPPLY OF PHYSICIAN SERVICES IN OECD COUNTRIES (2006),
available at http://www.oecd.org/ dataoecd/ 27/ 22/ 35987490.pdf (providing data
and analysis of the populations of most European countries and the amount of
doctors in those countries).
4. Specifically via "poor law, voluntary hospitals or private 'clubs'-as well as
from large numbers of alternative practitioners who offered medical care at a
cheaper rate." DIGBY, supra note 3, at 19.
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Today, medical services have become widely available in most
Western nations.5 This occurrence was the result of the decisions of
various governments to provide or oversee the provision of medical
services or, with some public encouragement, make the services part of
employment benefits. And so, the provision of medical care has
crossed the divide from being essentially a private matter to a public
one.
Most countries gradually came to the conclusion that they bear some
responsibility towards the well-being of their citizenry, or at least have
a compelling interest in making sure that needy citizens receive
medical care One could link this to a broader picture and note that
during the twentieth century the modern administrative state took
shape "reflecting the feeling that it was the duty of the government to
provide remedies for social and economic evils of many kinds."8
This is very loose phraseology, used intentionally, for it is well
beyond the scope of this paper to describe the extent, logic, and
ideology of the welfare state, its treatment in democratic theory or
even in the history of the various nations that have shown an active
interest in the health of its citizens.9 In sum, most modern nations have
5. This generally admirable achievement has had some detrimental effects as
the medicine, much like the law, has gradually shifted from a profession into a
business. See TAMAR FRANKEL, TRUST AND HONESTY, AMERICA'S BUSINESS
CULTURE AT A CROSSROAD 136-151 (Oxford Univ. Press 2006). See also M. Gregg
Bloche, Trust and Betrayal in the Medical Marketplace, 55 STAN. L. REV. 919
(2002) (elaborating on these detrimental effects).
6. Historically, it was German Chancellor Bismark who "embraced a
compulsory health care system financed by employee and employer contributions,
in which the wealthy contributed more than the poor." SUE A. BLEVINS,
MEDICARE'S MIDLIFE CRISIS 25 (Cato Inst., 2001). See also National Center for
Policy Analysis, Health Issues - Is Employer Health Insurance Really Cheaper?,
http://www.ncpa.org/ ba/ ba344/ ba344.html (last visited Nov. 15 2006)
("Employment-based health insurance covered 155 million Americans in 1998,
compared to only 15.5 million who purchase their own policies. People receiving
employer-based health insurance receive an enormous tax benefit, worth about
$141 billion in 2000... or 40 percent of the cost of coverage.").
7. See generally Elizabeth Docteur & Howard Oxley, Health-Care Systems:
Lessons from the Reform Experience, http://www.oecd.org/ dataoecd/ 5/ 53/
22364122.pdf (discussing reform measures taken by various nations of the world to
help the poor and disparate in the past several decades).
8. WADE & FORSYTH, supra note 2, at 3.
9. Wade and Forsyth stress that the expansion of voting rights allowed the
public to amass the political power necessary to form the national healthcare
service. Id. See generally PERSPECTIVES ON HEALTH AND HUMAN RIGHTS (Sofia
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concluded that the state must take part in providing, financing, and
overseeing the provision of medical care.'0
In legal terms, the questions (but not the answers) are relatively
straightforward: Is there a legal right to receive medical care? How is
such a right legally secured? What is the extent of such a right? Who
are its beneficiaries? What level of treatment and funding is granted to
them? The first two questions raise highly controversial matters of
principle. In the context of the "rights talk,"" there is significant
resistance to a recognition of social rights such as the right to medical
care, thus granting these rights the same constitutional protections that
have long been accorded more "conventional" rights and freedoms.
12
In several nations, the healthcare policy and practice is normally
established by statutes, regulations, and, where applicable, through
precedents put forth in case law. 13 Arguably, these methods are less
stable than a constitutional provision for the long-term continuity of
healthcare services. In essence, setting policy legislatively, judicially,
or through regulatory measures turns healthcare funding into welfare
payments: a type of discretionary spending the government makes out
of its kindness. '4 In hard budgetary times such funding may evaporate
when it is most sorely needed.'
5
Gruskin, Michael A. Grodin, George J. Annas & Stephen P. Marks eds.,
Routledge, Taylor & Francis Group 2005) (discussing the emergence of health and
human rights in relation to various aspects of the modern world).
10. See Docteur & Oxley, supra note 7, at 7-8. "[AlIt OECD countries rely
heavily both on public provision of insurance and on public regulation of various
aspects of health-care and private health-care insurance markets."
11. See MARY ANN GLENDON, RIGHTS TALK THE IMPOVERISHMENT OF
POLITICAL DISCOURSE (The Free Press 1991).
12. See Frank I. Michelman, The Constitution, Social Rights, and Liberal
Political Justification, 1 INT'L J. CON. L. 13 (2003) (analyzing the institutional,
contractarian and majoritarian objections to the constitutionalization of social
rights). See generally Cass R. Sunstein, Why Does the American Constitution Lack
Social and Economic Guarantees?, 56 SYRACUSE L. REV. 1 (2005) (analyzing
possible reasons why the American Constitution has not been interpreted to create
social and economic rights); M. Gregg Bloche & Elizabeth R. Jungman, The R
Word, 18 J. CONTEMP. HEALTH L. & POL'Y 633 (2002) (arguing that American
society is reluctant to recognize the possibility of rationing of healthcare).
13. See Colleen M. Flood, Lance Gable, & Lawrence 0. Gostin, Introduction
Legislating and Litigating Health Care Rights Around the World, 33 J.L. MED. &
ETHICS 336 (2005). Colleen M. Flood, Just Medicare: The Role of Canadian Courts
in Determining Health Care Rights and Access, 33 J.L. MED. & ETHICS 669 (2005).
14. See Susan L. Waysdorf, Fighting for their Lives: Women, Poverty, and the
Historical Role of United States Law in Shaping Access to Women's Healthcare, 84
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Yet even constitutional protection, where it exists, cannot
circumvent the political budgetary process. Constitutions that
recognize healthcare rights typically provide a declaration of intent
16rather than an "iron-clad" guarantee. Moreover, even the most
activist supreme courts have been hesitant in filling the vague
standards promised by their respective constitutions with concrete
demands on the public purse."
While jurists loath to admit it, the legal questions are subsidiary in
this instance. If this were merely a legal issue, one might expect to find
a huge gulf 18 between nations that seek to provide medical care to all
their inhabitants and nations that believe that their people should pay
Ky. L. J. 745, 749 (1995-1996) ("[H]istorically there have been at least two primary
models for health care delivery and care: first, universal health care coverage to all,
regardless of ability to pay; and second, the welfare medicine-medical apartheid
model, a policy-law paradigm linking government provision of health care to
economic status and to poverty.").
15. See generally David A. Super, The Political Economy of Entitlement, 104
COLUM. L. REV. 633 (2004) (analyzing entitlements generally and how they can be
maltreated by the American political system).
16. See e.g., S. AFR. CONST. 1996, §27, available at http://www.info.gov.za/
documents/ constitution/ index.htm.
Section 27. Health care, food, water and social security
1. Everyone has the right to have access to
a. health care services, including reproductive health care;
b. sufficient food and water; and
c. social security, including, if they are unable to support
themselves and their dependants, appropriate social assistance.
2. The state must take reasonable legislative and other measures,
within its available resources, to achieve the progressive realization of
each of these rights.
3.No one may be refused emergency medical treatment.
See also Eleanor D. Kinney & Brian Alexander Clark, Provisions for Health and
Health Care in the Constitutions of the Countries of the World, 37 CORNELL INT'L
L.J. 285 (2004) (providing an impressive overview of healthcare provisions in
constitutions of countries around the world).
17. See e.g., Soobramoney v. Minister of Health, Kwazulu-Natal, 1997 (12)
BCLR 1696 (S. Afr.). But see Paschim Banga Khet Mazdoorsamity v. State of West
Bengal, (1996) 4 S.C.C., available at http://judis.nic.in/ supremecourt/ qrydisp.asp?
tfnm=75597 (India) (finding an abrogation of a constitutional right when a state
hospital did not treat the plaintiff).
18. A gulf would be a difference in terms of public healthcare expenditure or
the number of people with healthcare problems covered by health insurance, for
example.
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their own way.' 9 In fact, the gulf is smaller than one might expect.
With the rising cost of medical care, no government can afford to
provide full medical coverage for its people. Take for example
America:
Total health care spending in the United States has been
growing faster than the economy for many years, and it is
projected to continue doing so. Between 1960 and 2003, national
health expenditure increased from 5.1 % of gross domestic product
to 15.3% - the result of an average annual growth rate 2.6%
higher than the economy as a whole. 0
In 2004, "the United States spent about $1.9 trillion for healthcare.
Real spending per capita increased from about $1,700 in 1975 to about
$6,300 in 2004 ....
In other words, when it comes to handling its healthcare system, the
United States, like all other Western democracies, reverts to the basic
public policy questions. How much money is the government willing
to spend on public-financing of medical treatment? Will it distribute
available funds according to the severity of the medical needs? Will
this distribution occur equally, among all the people? Or according to
a person's income? Will the government establish a public healthcare
system? Will the providers of such a system be private entities or will
there be a mix of the public/private sectors?
All modern Western governments seem willing to spend some public
22monies to provide or finance healthcare. The United States provides
a comprehensive national healthcare system with its Medicare program
(for those over the age of sixty-five and the disabled) and Medicaid
19. See e.g., Janis Sarra, Contemporary Corporate Theory Applied to the Health
Care Sector: A Canadian Perspective, 3 SEATTLE J. SOC. JUST. 345 (2004)
(discussing how Canada's healthcare system is centered on increasing the value of
its services, a goal quite different than the U.S. system).
20. CONGRESSIONAL BUDGET OFFICE, THE LONG-TERM BUDGET OUTLOOK 6
(2005), available at http://www.cbo.gov/ ftpdocs/ 69xx/ doc6982/ 12-15 -
LongTermOutlook. pdf (emphasis added).
21. Medicaid Spending Growth and Options for Controlling Costs Before the S.
Special Comm. on Aging, 109th Cong. 14 (2006) (statement of Donald B. Marron,
Acting Director, Congressional Budget Office), available at http://www.cbo.gov/
ftpdocs/ 73xx/ doc7387 07-13-Medicaid.pdf.
22. See supra note 7 and accompanying text.
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program (for the poor). 3  Regardless, these programs are bitterly
criticized from both sides for doing both too much and too little.24
Canada opted for a publicly-funded universal healthcare system which
is a source of national pride and joy, yet at the same time is facing its
own challenges. The controversial case of Chaoulli v. Quebec 5 attests
to such difficulties.26
At the end of the day, the conclusion seems clear: healthcare costs
are rising continuously and fast; governments are simply finding it
harder to pay for healthcare;27 and if they have ever been able to do so,
they cannot continue given the rising costs of medical treatment. Even
the world's wealthiest nation, the United States, may not be able to
afford such expenses.28 All of this means that some portion of the
medical coverage must remain for individuals to pay out of pocket.
23. See generally Maxwell J. Mehlman & Karen Visocan, Medicare and
Medicade: Are They Just Health Care Systems?, 29 Hous. L. REV. 835 (giving an
overview of both programs in relation to concepts of justice and equality).
24. For a provocative discussion of these issues, see RICHARD EPSTEIN,
MORTAL PERIL: OUR INALIENABLE RIGHT TO HEALTH CARE? (Addison-Wesley
1997). See generally, William P. Quigley, Five Hundred Years of English Poor
Laws, 1349-1834: Regulating the Working and Nonworking Poor, 30 AKRON L.
REV. 73 (1996)(discussion of English law on providing aid to the poor, which has
affected American laws and regulations); PAUL FRONSTIN, EMPLOYEE BENEFIT
RESEARCH INSTITUTE, SOURCES OF HEALTH INSURANCE AND CHARACTERISTICS
OF THE UNINSURED: ANALYSIS OF THE MARCH 2005 CURRENT POPULATION
SURVEY (2005), available at http://ssrn.com/ abstract=850465 (providing data and
Discussion on health insurance coverage of America's non-elderly).
25. See Chaoulli v. Quebec (Attorney General), [2005] S.C.R. 791 (The
Supreme Court of Canada ruling (4 to 3) that the Health Insurance Act and the
Hospital Insurance Act, in prohibiting private medical insurance, violated the
Quebec Charter of Human Rights and Freedoms. Three of the judges also finding
that the laws violated section seven of the Canadian Charter of Rights and
Freedoms). See also Recent Cases, Due Process - Right to Medical Access -
Supreme Court of Canada Holds That Ban on Private Health Insurance Violates
Quebec Charter of Human Rights and Freedoms - Chaoulli v. Quebec (Attorney
General), 2005 S.C.C. 35, 29272, [2005] S.C.J. No. 33 QUICKLA W (June 9, 2005),
119 HARV. L. REV. 677 (2005).
26. See generally Docteur & Oxley, supra note 7 (discussing developments in
OECD countries in the past decade and how they differ).
27. See ORG. FOR ECON. CO-OPERATION AND DEV., Rising Health Costs Put
Pressure on Public Finances, Finds OECD, June 26, 2006, http://www.oecd.org/
document/ 37/0,2340,en_ 2649 _201185 36986213_1_1_1_1,00. html.
28. See CONGRESSIONAL BUDGET OFFICE, supra note 20, at ix. "Even if
taxation reached levels that were unprecedented in the United States, current
spending policies could become financially unsustainable."
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Canada may be the outlier, but most countries, including Israel and
perhaps the United States, are seriously contemplating how to ration
healthcare in an equitable and transparent manner.
2 9
This paper presents a novel introduction to the Israeli healthcare
system. The system is described generally in Part II. Part III discusses
in detail one of its main features: the Healthcare Basket Committee
(Committee). This government committee is entrusted with life-and-
death decisions by deciding which new medications, medical
procedures, and technologies should be annually added to the Israeli
medical services "basket." Criticism of the Committee is presented in
Part IV. The final section of the paper, Part V, addresses a unique
feature of Israeli healthcare policy: the decision to include fertility
treatment in the "healthcare basket" and, thus, have this treatment
receive heavy government subsidization. This case study helps better
understand the impact of the Committee on Israeli society. This paper
aims to make a small contribution to the rich and lively debate on the
regulation and the management of public healthcare systems by
highlighting that of the state of Israel.
II. THE ISRAELI HEALTHCARE SYSTEM - A SHORT PRIMER
The story of the Israeli healthcare system can be divided into two
eras: the first being from foundation of the system to the great changes
of the mid-1990s, and the second from 1994 to the present.3°
A. Before the "Revolution"
From 1517-1917, during the long rule of the Ottoman Empire in the
Middle East, medical services were mostly provided by charitable and
religious organizations with minimal government intervention.31
29. See Colleen M. Flood, Lance Gable & Lawrence 0. Gostin, Introduction:
Legislating and Litigating Health Care Rights Around the World, 33 J.L. MED. &
ETHICS 636, 638 (2005); Thomas R. McLean, Medical Rationing: The Implicit
Result of Leadership by Example, 36 J. HEALTH L. 325 (2003) (arguing for
America to consider rationing healthcare).
30. There is relatively limited academic literature in either English or Hebrew
on the Israeli healthcare system. Therefore, in this section, unless otherwise
stated, this article relies mostly on Hebrew textbooks dealing with the topic.
31. Various European nations and Christian organizations set up healthcare
institutions both to care of pilgrims, and for to gain a political foothold in
Palestine. There were also Jewish charities that provided medical services. In
1912, there were about 50,000 Jews in Palestine, and only thirty-two Jewish
medical doctors. See GABI BIN NUN, YITZHAK BERLOVITZ & MORDECHAI SHANI,
THE HEALTH SYSTEM IN ISRAEL 23 (Ministry of Defense Publication 2005).
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Matters changed during the British mandate of the land (ca. 1917-
1948). First, after World War I, aid from the Jewish-American
community allowed the establishment of Hadassah, a hospital and
clinic chain, throughout the land. While Hadassah gradually
relinquished control over most of its institutions, the organization left
its mark by establishing a highly professional nonpolitical medical
service.32 Second, diametrically opposed to Hadassah were the medical
cooperatives established after 1911 by the powerful and highly
ideological political parties. The formation of these institutions
created a longstanding rift between the sectarian and the government-
controlled hospital systems.33 Also, in the mid 1930s, a stream of
medical personnel arrived as refugees from Central Europe. Many of
these refugees established private practices and hospitals.34 Finally, the
British mandatory government established a health department, the
precursor to Israel's Ministry of Health. This department dealt mostly
with public health issues such as fighting malaria and other infectious
diseases. Over time it began to run hospitals directly, laying the
foundations of the current multifaceted government role in
healthcare."
The most significant factor in Israeli healthcare is the Kupot Holim
(KH). The first KH was founded by labor leaders on a firm ideology
of mutual help in 1911 to secure medical services for laborers. Its
original articles of association state that each member is willing to
physically keep night-vigil next to another member's sickbed, or find a
32. Hadassah is now centered in Jerusalem. See id. at 24-26; SHIFRA SHVARTS,
KUPAT HOLIM, THE HISTADRUT AND THE GOVERNMENT THE FORMATIVE YEARS
OF THE HEALTH SYSTEM IN ISRAEL, 1947-1960, at 16-18 (Hamakhpil Banegev Press
2000). See generally Hadassah Medical Center, http://www.hadassah.org.il/ English
(last visited Nov. 17, 2006) (the website of Hadassah).
33. See BIN NUN ET AL., supra note 31, at 26-27; SHVARTS, supra note 32, at 10-
11.
34. Their number is estimated at 1,200, about 75% of all Jewish doctors in the
land. With supply greater than demand, making a living was difficult for them.
See BIN NUN ET AL., supra note 31, at 25; SHVARTS, supra note 32, at 28-30.
35. The Ministry of Health is a major provider of inpatient services and owns
about a third of all hospital beds, public health services and ambulatory psychiatric
care. See Revital Gross, Implementing Health Care Reform in Israel:
Organizational Response to Perceived Incentives, 28 J. HEALTH POL. POL'Y & L.
659, 663 (2003); BIN NUN ET AL., supra note 31, at 26. For current data on Israeli
hospitals, see ISR. CENT. BUREAU OF STATISTICS, HEALTH SERVICES HOSPITALS,
BY TYPE AND OWNERSHIP 1, http://wwwl.cbs.gov.il/ shnaton56/ st06_05.pdf.
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replacement should he be unable to keep this obligation.36  These
healthcare associations were loosely modeled (and indeed, named)
after Bismark's healthcare provision model that had developed in
Central Europe.37 In 1920 these various cooperatives united into the
general healthcare cooperative of the Jewish laborers in Palestine,
Kupat-Holim Clalit (KHC).38
KHC became, and still is, the dominant healthcare provider in
Israel.3 9 There are two final wrinkles to this story. KHC was deeply
linked with the Israeli labor movement, the dominant political force in
the country until 1977. In 1937, a link was made between membership
in the labor trade union and the KHC, and both fees were collected
together. In other words, to enjoy KHC healthcare, one had to be a
member of the workers' trade union, and vice versa. This linkage, one
that greatly empowered the trade union and the Labor Party, was only
severed in the reform of the mid-1990s. 4° Additionally, the political
linkage made many people uncomfortable enough to join the much
smaller KHs, which were not all politically affiliated.41
36. See BIN NUN ET AL., supra note 31, at 26-27; SHVARTS, supra note 32, at 10-
12.
37. The associations were called Kupat Holim, literally a translation of the
German word Krankenkasse, or sick-fund. In recent years, the KHs have dropped
this name in favor of the term "healthcare services." See BIN NUN ET AL., supra
note 31 at 26-27; SHVARTS, supra note 32, at 10-13.
38. See BIN NUN ET AL., supra note 31, at 27; SHVARTS, supra note 32, at 18-20.
39. Clalit means "general." See BIN NUN ET AL., supra note 32, at 26-27;
SHVARTS, supra note 32, at 19-23. See also Clalit Health Services,
http://www.clalit.org.il/ clalitE/ default.asp (last visited Nov. 17, 2006) (English
website for KHC, including a history). 2005 figures suggest Clalit, with income of
around $3.8 billion, served 53% of the insured population and had 68% of the
available branches. Maccabi was second with an income of $1.4 billion, serving
24% of the insured and having 17% of branches (together with independent
medical practitioners). See Roni Linder-Ganz, BDI Rating: Clalit Healthcare
Services is First - 17 Billion NIS in Income, 53% of the Insured, HA'ARETZ (Isr.),
June 19, 2006, available at http://www.haaretz.co.il/arch (article available in
Hebrew via subscription).
40. See BIN NUN ET AL., supra note 31, at 27-28; SHVARTS, supra note 32, at 28.
41. See BIN NUN ET AL., supra note 31, at 28-32; SHVARTS, supra note 32, at 27,
29. The services of the smaller KHs were not available everywhere in the country.
Figures from 1948 suggest that the KHC covered 85% of the insured population.
See BIN NUN ET AL., supra note 31, at 27-32, tab. 1.1, at 32; SHVARTS, supra note
32, at 25-28. See generally, Maccabi Health, http://www.maccabi -health.co.il/
english-site/ index.html, (last visited Nov. 17, 2006); Leumit,
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This state of affairs continued, virtually unchanged, from the
foundation of Israel in 1948 until 1995.42 Years of political pressure
have brought little change. Only the Labor Party's political decline
and growing public dissatisfaction with the current system
(beleaguered with strikes, long queues, etc.) finally brought change.
The report of a public committee, headed by Israeli Supreme Court
Justice Shoshana Netanyahu, in the 1990s, broke the impasse and
precipitated the passage of the National Health Insurance Act, 5754-
1994 (1994 Act 43), and two years later, legislation of the Patients'
Rights Act, 5756-1996 (1996 Act). 44
B. The Changes of the Mid-1990s
These two acts were meant to update and clarify the duties of the
State regarding the provision of healthcare and the legal rights of the
patients in receiving such treatment. The 1994 Act was designed to
financially stabilize the healthcare system, provide "universal health
insurance coverage, clarify [peoples'] rights to health insurance
coverage, increase freedom of choice and transfer among the [KHs] ,"
and improve the quality and equality of services provided.4 ' The 1996
Act basically "embodies a movement from paternalism to autonomy in
doctor-patient relations., 46 Specifically, its purpose was to "establish
http://www.leumit.co.il/ eng/ (last visited Nov. 17, 2006) (English websites for both
Maccabi Healthcare Services and Leumit healthcare, two smaller KHs).
42. But not unchallenged; political considerations hindered major reforms. See
BIN NUN ET AL., supra note 31, at 33-36; SHVARTS, supra note 32, at 143, 162-174,
182-185, 201-210, 231-234. See also Gross, supra note 35, at 663-664.
43. Author's note: The 1994 Act was passed in mid 1994 but did not go into
effect until January 1, 1995. ISR. MINISTRY OF HEALTH, OMBUDSMAN FOR THE
NAT'L HEALTH INSURANCE LAW 1, http://www.health.gov.il/ download/ docs/ units/
complaints/ doe/ english.doc (last visited Feb. 9, 2007). Therefore, some of the
sources cited herein refer to a health law passed in 1995, which would be
synonymous with the 1994 Act.
44. See CARMEL SHALEV, HEALTH AND HUMAN RIGHTS IN ISRAELI LAW 145-
47 (Ramot-Tel Aviv Univ. 2003).
45. Gross, supra note 35, at 665-66. "Prior to [the 1994 Act], insurance
coverage was incomplete: 4 % of the total population and as much as 12% of the
[Arab-Israeli] population did not belong to a [KH]." Id. at 664. See also SHALEV,
supra note 44, at 159 (putting the number at about 250,000 people).
46. Carmel Shalev, Efrat Freiman, Monitoring Patients' Rights-A Clinical
Seminar, 21 MED. & L. 521, 521 (2002).
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the rights of persons seeking or receiving medical care . . . and to
protect their dignity and privacy."47
Of particular relevance to this paper is the 1994 Act, which changed
Israeli healthcare in several regards. First, it contains a clear national
commitment that every resident of Israel (not just citizens) has the
right to obtain healthcare services under the Act, regardless of his or
her ability to pay. The government is responsible for funding these
medical services from a "basket". The source of such funding would
be from patients' premiums and the national budget.
48
Second, healthcare services are still to be provided by the KHs, but
with a twist: the political linkage is severed, and the health insurance
premiums henceforth would be collected by the National Insurance
49Institute, a state agency, as a tax that every employee must pay
(generally, at a level of "4.8% of income, with reductions granted for
the elderly and poor"). 0
Third, measures were taken to ensure that people could freely
transfer among KHs and that resources would be distributed among
KHs according to health needs, with "increase[d] equality in the
provision of services to different populations and geographic areas."51
To ensure freedom of choice and transfer among KHs, the 1994 Act
"prohibits sick funds from rejecting candidates for membership. 5 2
Finally, and most directly pertinent for this paper: in an attempt to
eliminate competition over the range of services, the 1994 Act defined
a standard benefits package, the so-called medical services "basket.
5 3
Once healthcare premiums and benefit packages became uniform,
"planners intended [KHs] to compete only over the quality of
47. Id. at 522 (quoting Patient's Rights Act of 1996).
48. See SHALEV, supra note 44, at 159-160, 179-185. See also U.N. Human
Rights Committee, Initial Report of States Parties Due in 1993: Israel, art. 6, U.N.
Doc. CCPR/C/81/Add.13 (Apr. 9 1998).
49. See SHALEV, supra note 44, at 152-156, 161, 202-204.
50. Gross, supra note 35, at 667.
51. Id. at 666. Prior to the 2004 act, the four KHs competed over premium
fees and provided different benefit packages. See id. at 664.
52. ld. at 668. Thus, the law prohibits what is known as "cream skimming."
Id. "Cream skimming results when suppliers seek to reduce their costs by
declining to provide goods and services to "high cost" voucher recipients."
Michael J. Trebilcock, Ron Daniels & Malcolm Thorburn, Government by
Voucher, 80 B. U. L. Rev. 205, 212 (2000). For a discussion of these and other
aspects of the 1994 Act, see Gross, supra note 35, at 667-72; SHALEV, supra note 44,
at 194-96.
53. Gross, supra note 35, at 668.
Regulating Life and Death
services. 54 The 1994 Act set forth a standard benefits package for all
in order to "simplify comparison among sick funds and provide a
minimum level of reasonable care."55  Furthermore, "[t]he cost of
providing this standard benefits package was set in the [1994 Act,] and
a mechanism for updating the cost was devised."56
It is at this point in history that the story finally begins. Two specific
examples pertaining to the Israeli Basket will be discussed. The first
example, which constitutes the bulk of the paper, concerns the
committee entrusted to update the Basket with new medications,
procedures and technologies. The second is a short discussion of the
Israeli policy decision to publicly finance fertility treatments via the
Basket.
Ill. THE ISRAELI HEALTHCARE "BASKET CASE"
A. Controlling Costs
By international standards, the Israeli healthcare system is not very
costly. The national healthcare expenditure in Israel is equivalent to
the average of countries in the Organisation for Economic Co-
operation and Development (OECD), and well below the American or
German standards. 7 Moreover, Israeli expenditures on medications
are on the frugal side."
The 1994 Act provided two mechanisms for adjustment of the
Basket's expenditure level. The first is an automatic update, based on
several economic indices, "including the Health Price Index published
by the [Israeli] Central Bureau of Statistics and demographic
parameters linked to population growth and aging."5 9 Additionally,
the law implemented a more discretional mechanism that permitted
the Minister of Health to make changes to the basic Basket services.
Any changes resulting in increased cost, however, require consent of
both the Israeli Treasury and government, i.e., the entire Israeli
cabinet. 0
54. Id. at 668.
55. Id. at 666.
56. Id. at 667. See also SHALEV, supra note 44, at 160-61, 201-02.
57. See Press Release, Isr. Cent. Bureau of Statistics, Continuing Decrease in
the Share of the Nat'l Expenditure on Health Our of Gross Domestic Product 6
(Aug. 28, 2006), available at http://www.cbs.gov.il/ hodaot2006n/ 006j183e.pdf.
58. See id. at 3.
59. Gross, supra note 35, at 667.
60. See SHALEV, supra note 44, at 212-213, 229-230, 266-267. In addition, the
Minister of Health and the Minister of Finance are to monitor the KHs' financial
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At first the statutory framework appeared fine, but when political
and economic realities entered into the equation, the Basket ended up
never being fully updated. 6' The problem was the government's
reluctance to adjust the real-value (as opposed to the nominal value)
of the Basket. This unwillingness occurred through various
administrative and economic means, primary among them reluctance
to update the Basket to accurately reflect demographic,
pharmaceutical, or technological changes.62
As a result, government and local authority participation in the
financing of national health expenditure saw an initial jump from just
less than 50% in 1994 to 74.5% in 1996. This increase then saw a
steady decline to a current funding level of 66%-68%.63 As for the
Basket, its cost has remained somewhat stagnant, 64 possibly reflecting
its gradual erosion.
performance, to ensure they remain financially viable. Gross, supra note 35, at
667.
61. Indeed, in 1997 the government had legislation passed that cancelled
employers' obligation for co-payments towards medical insurance of employees, a
major source of income of the national health insurance. For information on the
political background, see SHALEV, supra note 44, at 218-32.
62. The update for demographic changes (size and aging of the population)
was at a rate of 2% per year, while it was estimated to be, in fact, 3.7% per year.
As for adjustment of the healthcare basket on the basis of technological changes,
the 1994 act did not contain any reference to this update. Some view this as a
reflection of the tension between national economic interests, basically an attempt
to limit medical expenditures, and the interests of the national health system, in
the form of medical and technological advances. Id. at 208. Starting in 1998, the
Treasury allowed updating for technological changes, but only at a rate of 1% to
1.5% per year, while estimates place the real figure at 2% to 4% per year. For the
various measures used to preclude the full update of the Basket, see id. at 229-32.
See also HCJ 2344/98 Maccabi Healthcare Services v. The Minister of Finance
[2000] IsrSC 54(5) 729 (involving a denied petition to the Supreme Court of Israel
asking that it order the government to fully update the basket).
63. ISR. CENT. BUREAU OF STATISTICS, NAT'L EXPENDITURE ON HEALTH, BY
OPERATING SECTOR AND FINANCING SECTOR 1, http://wwwl.cbs.gov.il/ shnaton56/
st06_03.pdf.
64. See JONATHAN EHRLICH & AMI ZADIK, KNESSET RESEARCH AND
INFORMATION CTR., IN PREPARATION FOR THE 2007 BUDGET: SOCIAL
EXPENDITURE - REFERENCE TO SELECTED ToPics (2006) available at
http://www.knesset.gov.il/ mmm/ data/ docs/ m01499.doc (source only available in
Hebrew).
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B. How to Expand the Basket?
As mentioned, the 1994 Act established the Basket with a highly
specific and detailed list of health services to which every Israeli was
entitled. Several problems soon became apparent. First, the makeup
of the Basket was not formulated properly. The Basket was simply the
result of the adoption of an existing grouping of health and medical
services, rather than a careful examination of what was currently
available. 65 Further, both the contents of the Basket and the amount of
funds available for its financing depended on the complicated political
budgetary process of Israel.66  Third, the written commitments
regarding the contents of the Basket turned out to be a double-edged
sword. In specifically detailing the Basket's contents and its cost,
patients' fears of arbitrariness and vagueness regarding the medical
services that the KHs must provide was somewhat dispelled. The
definition, however, also brought about an assumption of
conclusiveness in that it was obvious what was contained in the
Basket.67 Finally, and most importantly, there was no mechanism to
update the Basket for technological changes or advancements in
medicine.
In the first few years after the 1994 Act went into effect, all of these
troubles became evident and public discomfort began to grow. The
people wondered who will pay for services not contained in the Basket
or for new medical procedures and medications. Such problems were
of no concern to the wealthy; they either bought supplementary
insurance"' or paid out-of-pocket for services not included in theBasket.69
65. SHALEV, supra note 44, at 160-161.
66. See Carmel Shalev and David Chinitz, Joe Public v. General Public: The
Role of the Courts in Israeli Health Care Policy, 33 J. L. MED. & ETHICS 650, 651
(2005); SHALEV, supra note 44, at 254 (noting that there are, in fact, some
differences between the healthcare baskets provided by the four KHs so that there
are currently four different baskets available, each defining the services provided
under the Act and the prescribed payment for them).
67. This interpretation of the Act was also accepted by the courts. See
SHALEV, supra note 44, at 265-66.
68. See SHALEV, supra note 44, at 205-06, 255-58, 262-63. The 1994 Act allows
the KHs to offer, for an additional fee, "supplemental insurance for services not
included in the standard benefits package; this has created a niche in which
competition over premiums and the scope of services can and does take place..
Gross, supra note 35, at 668.
69. See generally BRUCE ROSEN ET AL., WORLD HEALTH ORGANIZATION, THE
EUROPEAN OBSERVATORY ON HEALTH CARE SYSTEMS, HEALTH CARE SYSTEMS IN
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These first few years of the Basket were marked with almost total
stagnation. Despite numerous requests to expand services, not much
happened. In particular, only two drugs had been added by December
1997, despite frequent requests. The only reason these drugs were
included was "due to aggressive legal action taken by an organised
group of patients with multiple sclerosis[,] ' 70 backed by political
pressure from both the Minister of Health and Knesset members who
joined forces against the Treasury. 1
In sum, several facts became abundantly clear: first, there was a real
need to expand the Basket and its budget; second, that healthcare
providers would be driven to the Basket despite the cost of rising
deficits, whether the government approved such spending or not; third,
that expansion of the Basket was fiscally problematic but politically
72very popular.
C. First Things First: Let's Form a Committee
As is common knowledge for any student of government, there are
plenty of budget disputes between government ministries, interest
groups, and the treasury. Most of them, regardless of how much
money is involved, hardly hold the public's attention. In this light,
however, the Israeli Basket proved quite different. In particular, the
Basket is the concern of every person and every family in Israel; most
focus on the highly dramatized fact that the Basket Committee deals
with life-saving drugs." Its deliberations became a modern, public
gladiator bout, with Committee members having the power to thumb-
TRANSITION: ISRAEL 29-31 (Sarah Thompson & Elias Mossialos eds. 2003),
available at http://www.euro.who.int/ document/ E81826.pdf #search= %22co%20
payments% 20medical% 20healthcare% 20israel% 200ECD% 22 (providing
further explanation of co-payments being paid out of pocket in Israel).
70. David Chinitz, Carmel Shalev, Noya Galai, Avi Israeli, Israel's Basic
Basket of Health Services: the Importance of Being Explicitly Implicit, 317 BRIT.
MED. J. 1005, 1005 (1998).
71. Zvi Zerahia, The Threat Worked, HA'ARETZ (Isr.), Jan. 12, 1996 available
at http://www.haaretz.co.il/ arch (article available in Hebrew via subscription).
72. See Chinitz et al., supra note 70, at 1006-07.
73. See infra nn. 79, 84 & 97 and accompanying text. An interesting topic
worthy of future consideration would be the issue of the Israeli healthcare basket
committee's specific decisions in view of the extensive literature dealing with the
statistical value of life from a governmental perspective. See e.g., Cass R. Sunstein,
Lives, Life-Years, and Willingness to Pay, 104 COLUM. L. REV. 205 (2004)
(discussing how the government should consider the value of a statistical life when
performing cost-benefit analysis).
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up for life or thumb-down for death. This accounted for growing
public interest and scrutiny of what is essentially an internal
professional advisory government committee, with only limited public
representation among its members. A full analysis of the Committee's
operation is beyond the scope of this paper; only the a brief summary
of highlights will be presented.
The potential high drama that the updating of the Basket could raise
was revealed early on as cancer patient Tali Levy appeared, in a
nationally televised event, before the Israeli Knesset's Labor, Welfare,
and Health Committee:
[a]nd in a heart-wrenching performance [Levy] asked to be
allowed to live . . . following this appearance two things
happened: 14 vital medications were immediately added to the
basket at a cost of 150 million NIS, and a public committee was
formed for running updates of the basket. Members of the
committee are representatives of the ministry of health, the
Kupot Holim, the medical association, representative of the
treasury's budget division and public representatives. I may say
that this committee, of whom I am member, is unique in the
world and does excellent work. The deliberations are conducted
with full transparency and on the basis of accurate information,
74and decisions are reached through consensus.
As public anger began to rise, patients began voicing their
grievances.75 Reacting in true bureaucratic style, the decision was
taken by the Israeli government to allow the Committee to stipulate
76physical and temporal access to the Basket.
74. Yiftah Goldman, The Healthcare Basket is Ill, Social-Democratic Israel,
Dec. 12, 2004, http://www.yesod.net/yesod/archives/2004/12/post_75.htm
(interview with Dr. Yoram Blashar) (website in Hebrew). See also Chinitz et al.,
supra note 50, at 1106.
75. See, e.g., Ran Resnik, Joseph Sherman's Last Hope, HA'ARETZ (Isr.), July
30, 1998, available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription)
Joseph Sherman, cancer patient is a member of Kupat Holim Klalit and
insured in 'Dikla' complimentary insurance. Yet the Kupa refuses to
finance for him the single treatment that may save his life. A report
published today holds: it is unreasonable that the Kupot Holim deny
medical treatment of the severely ill.
Id.
76. Chinitz, et al., supra note 70, at 1005, 1006. Additionally, the 1994 Act
allowed for the establishment of an advisory council for health issues and the
Basket. Id. at 1005.
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D. It May be a Mess -But What a Fascinating Mess, Indeed!
As a matter of Israeli administrative law and function, the
Committee has been highly problematic since its inception. It does not
conform to formal or traditional committee models to which the Israeli
public has grown accustomed, and since its formation it has been
relatively secretive in its operation.7 Despite a lack of information
concerning the origins of the Committee, it seems likely that the
Committee was initially formed merely as a professional, non-political,
advisory body to the Health Ministry. Israeli law allows for such an
occurrence under the government's auxiliary or residual powers which
allow it to take non-substantive steps for the operation of
71bureaucracy.
Providing, rather kindly, that government decision-makers operated
under this original intent, this assumption turned out to be a
miscalculation. The Committee soon became
the most important allocations committee in the country. It is
important not only because it allocates millions of shekels every
year for the purchase of medications and medical technologies;
and not only because every decision it makes puts a drug or
treatment into the basket of services for many years, and
therefore the sums involved are not in the hundreds of millions
of shekels, but in the billions of shekels. It is important primarily
because every decision it makes affords life and quality of life to
hundreds and thousands of people. The committee members
determine who will live and for how long, and how much pain
and how many side effects patients will suffer.79
77. See, e.g., Haim Shadmi, The Health Council- Many Functions but Little
Influence, HA-ARETZ (Isr.), Dec. 19, 1999, available at http://www.haaretz.co.il/
arch (article available in Hebrew via subscription); Haim Shadmi, Precisely What
Power Does the Committee for the Expansion of the Health Basket Operate?, HA-
ARETZ (Isr.), Feb. 4, 2002, available at http://www.haaretz.co.il/ arch (article
available in Hebrew via subscription); Ran Reznik, The Health Council Approved
the Expansion of the Healthcare Basket, HA'ARETZ (Isr.), Apr. 7, 2005, available at
http://www.haaretz.co.il/ arch (article available in Hebrew via subscription)
(stating that the Council approved the recommendations of the public committee
for the explanation of healthcare services).
78. Knesset, Basic Law: The Government (2001), para. 32, http:// www.
knesset. gov. ill laws/ special/ eng/ basicl4_eng.htm (last visited Jan. 12, 2007).
79. Ilan Shahar, 270 New Political Appointments, HA-ARETZ (Isr.), Aug. 18,
2005, available at http://www.haaretz.com/ hasen/ pages/ arch/ rchBuyArt.jhtml
(article available via subscription in English).
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As discussed later, these enormous pressures and interests
involved-public, political, personal, and financial -overburdened the
Committee, bringing it to the verge of resignation, as well as a loss of
public credibility and support.80
E. How and Why the Committee Works Out in the End
Reports on the workings of the Committee are incomplete. From
available records it seems that the Committee was first appointed only
by the Minister of Health, more recently by both the Minister of
Health and the Minister of Finance.8  We also know that the
Committee examines a very large number of new medications,
procedures, and technologies offered for inclusion in the Basket.
82
Submissions are filed with the Ministry of Health, which studies each
proposal and prepares for the Committee background materials
analyzing the item offered, its functions and alternatives, the estimated
number of patients who might benefit from it, and its cost.83 The
Committee has established a 10-tier ranking system: at the top of the
scale (receiving an "A10" rating) are life-saving medications, followed
by medications that have the potential to significantly improve
80. See infra Part IV.
81. In 1999, the government approved Minister of Health Joshua Matza's
recommendations for additions to the healthcare basket; that same year, the
committee is first mentioned as a "committee on behalf of the Health Ministry."
See Iris Krause, New Medical Technologies Placed in the Healthcare Basket,
HA'ARETZ (Isr.), Mar. 8, 1999, available at http://www.haaretz.co.il/arch (article
available in Hebrew via subscription); Haim Shami, Committee Faces Tough
Choices on Next Year's Health Basket, HA'ARETZ (Isr.), Dec. 8, 1999, available at
http://www.haaretz.com/ hasen/ pages/ arch/ ArchBuyArt.jhtml (article available
via subscription in English); Haim Shami, The Committee Whose Function is to
Expand the Healthcare Basket was Appointed, HA'ARETZ (Isr.), Oct. 31, 2000,
available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription) (Minister of Health Ronni Milo appointed 23 committee members);
Haim Shami, The Make-up of the Committee that is Meant to Expand the
Healthcare Basket in 2002 was Approved, HA'ARETZ (Isr.), Oct. 29, 2001, available
at http://www.haaretz.co.il/arch (article available in Hebrew via subscription)
(Minister of Health Nissim Dahan appointed to the Committee together with the
Minister of Finance).
82. See infra Part III E.
83. For the Israeli government's instructions in order to include a drug in the
Basket under the 1994 Act, see ISR. MINISTRY OF PHARM. HEALTH, GUIDELINES
FOR THE SUBMISSION OF A REQUEST TO INCLUDE A PHARM. PROD. IN THE NAT'L
LIST OF HEALTH SERVICES (2004), available at http:// www.health.gov.il/
download/ forms/ a28_ aclalaeng2002 .doc. See also Goldman, supra note 74.
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patients' lives ("A09"). These rankings are followed by important but
less vital medications, ranked "B" and lower.84
While there is a significant amount of public criticism leveled against
the Committee,8 its professionalism and discretion have remained
relatively unblemished 86 and its decisions on the specific medications to
be included in the Basket remain the final word on the topic. There
84. See Goldman, supra note 74. A report of the Knesset Research
Department speaks of five main categories for medications, services and
technologies that are considered by the committee. These products can: (1) help
the survival of the patients (saving or extending life); (2) improve quality of life;
(3) rehabilitate the patient; (4) help prevent and; (5) diagnose. See BARUCH LEVI,
KNESSET RESEARCH DEPARTMENT, OVERVIEW ON DRUGS AND TECHNOLOGIES
CONSIDERED FOR INCLUSION IN THE HEALTHCARE BASKET (2004), available at
http://www.knesset.gov.il/ MMM/ data/ docs/ m01002.doc (document in Hebrew)
[hereinafter KNESSET RESEARCH DEPARTMENT, OVERVIEW]. This all looks
reasonable enough, but some experts suggest different methods, such as adopting
the Quality Adjusted Life Years standards. See Boaz Ginzburg, Medications that
Worth More and Medications that are Worth Less, HA'ARETZ (Isr.), Mar. 28, 2005,
available at http://www.haaretz.co.illarch (article available in Hebrew via
subscription); Yuval Yoaz, Chronic Skin Disease Patient Petitions the Supreme
Court: Hospitalization is More Expensive than the Medication, HA-ARETZ (Isr.),
Mar. 21, 2005, available at http://www.haaretz.co.illarch (article available in
Hebrew via subscription).
85. See infra Part IV.
86. For example, one critique was that the Committee mostly thinks about the
short-term, but this is the result of a Ministry of Health policy requiring evaluation
of a proposed product's potential effects for the first three years of inclusion in the
Basket. See Haim Shadmi, The Healthcare Committee Only Thinks about the Short
Term, HA'ARETZ (Isr.), Jan. 10, 2001, available at http://www.haaretz.co.illarch
(article available in Hebrew via subscription). See e.g., Ran Reznik, The
Medication Could Have Alleviated the Suffering of Brain Cancer Patients, but It
Will Damage the Position of the Oncologists, HA'ARETZ (Isr.), Mar. 2, 2004,
available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription) (the press suggesting that the Basket's decision not to pay for a
brain-cancer medication is part of a larger medical controversy between
oncologists and neurosurgeons). Nevertheless, the expertise and foresight of the
Committee has also been touted in the press. A Committee member was quoted
as saying that the Committee needs to consider dealing with common illnesses that
affect most of the population, rather than just a small portion. The Committee
member announced this standard when the Committee was determining whether a
pneumonia-shot for the over-sixty-five population should be part of the Basket or
not. See Haim Shadmi, Panel Opposes New Antibiotics for Health Basket,
HA'ARETZ (Isr.), Dec. 23, 2001, available at http://www.haaretz.com/ hasen/ pages/
arch/ ArchBuyArt.jhtml (article available via subscription in English).
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are a few possible reasons for this deference and respect. First,
Committee members are typically senior healthcare officials who are
distinguished and well-respected public figures. Their work on the
Committee is considered a public duty not envied by most.
87
Moreover, the enormous pressures from interest groups and politicians
mean that there is no viable alternative decision-making body in Israeli
public life that could replace the Committee and still enjoy an equally
high level of public trust. The only comparable entity in Israeli public
life, the Supreme Court, has shown little interventionist inclination. 8
Indeed, the highly activist Israeli Court89 has recently rejected
petitions concerning the exclusion of new medications and procedures
from the Basket. In a recent decision, Israel's highest court described
the procedure for expansion of the Basket. The Court stated, with
concern and honesty, but also with atypical deference, that "[n]o
person can deny, first that we are talking about an orderly decision-
making process and second, that prioritization is necessary in the
circumstances of the healthcare basket." 9 If public advocacy groups
that joined the petition in this case had hoped the Court would
substantially review the Committee's decision and find improprieties in
its operation, they were surely disappointed.9'
87. See Judy Siegel-Itzkovich, The Basket Case, JERUSALEM POST, July 10,
2005, at 7 (discussing the scandals and tough decisions faced by the Committee).
88. See Ze'ev Sternhell, Public Opinion is Dead, HA'ARETZ (Isr.), Dec. 8, 2006,
available at http://www.haaretz.com/ hasen/ spages/ 797943.html ("No less
dangerous is the Supreme Court's decision to shut itself in to a narrow
interpretation of its role.").
89. Yoav Dotan, The Spillover Effect of Bills of Right: A Comparative
Assessment of the Impact of Bills of Right in Canada and Israel, 53 AM. J. COMP. L.
293, 332, (2005) ("there is a widespread consensus among various commentators
that the Israeli Supreme Court can be described as a very activist court (some
argue, one of the most activist courts in the world).").
90. HCJ 2974/06 Isareli v. The Healthcare Basket Expansion Committee [2006]
at 7, available at http://elyonl.court.gov.il/ Files/06/ 740/029/ t03/ 06029740. t03.pdf
(document in Hebrew).
91. Lower courts have intervened in some petitions concerning the actual
supply of medical services by KHs, sometimes requiring them to provide medical
services against their wishes and judgments. See, e.g., Roni Linder-Ganz, A Judge
Mandated Meuhedet to Fund Medication for a Cancer Patient, HA'ARETZ (Isr.),
Dec. 7, 2005, available at http://www.haaretz.co.il/arch (article available in Hebrew
via subscription) (The spokesperson of a sick fund, Kupat Holim Meuhedet, said
the holding was incompatible with the 1994 Act). See also Shalev and Chinitz,
supra note 66, at 655, 656.
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A third reason for such high regard is ironically derived from the
Committee's chief complaint: that it is under-funded. 9 This lack of
funding means that the Committee, being guided by efficiency, mostly
approves life-saving medications and treatments that have the most
potential to significantly improve patients' lives. These products are at
or near the top of its priority list. The decision to include them in the
Basket is well within the consensus and beyond serious public
challenge. 93
IV. CRITICISM OF THE COMMITTEE'S OPERATIONS
This section identifies various critiques of the Committee. The
relative merit of the critiques will be evaluated. Finally, the major
overhaul currently planned for the Committee will be explained.
Unfortunately, with instability of the Ehud Olmert government, 94 it is
difficult to predict a timeline for the planned reforms.
Most criticism of the Committee are functional in character, dealing
with the operation, membership, and decision-making process. No
one doubts the need for a "health care basket" in general, or that the
Committee is a high-caliber, professional body that makes reasonable
and equitable decisions.
A likely source of most problems observed by critics is that the
Committee outgrew its humble beginnings and assumed public
significance beyond original expectations. After all, it can be said that
the Committee was only created as an internal, ministerial, advisory
body. It is akin to a country road which has turned into a highway,
without the necessary planning, approvals, or logistical changes. There
is only so much that the Committee can do with the enormous burden
now before it.
How and why the Committee assumed such responsibility is
relatively clear and involves several factors. To begin with, under the
1994 Act the government is responsible for funding the Basket.9 It has
92. Those on the current Committee have noted that in 2006 the size of the
budget restricted the amount of proposals the Committee was able to accept. See
Mordechai Shani, The Heart of the Health-Basket, HA'ARETZ (Isr.), June 5, 2006,
available at http://www.haaretz.com/ hasen! pages/ arch/ ArchBuyArt.jhtml (article
available via subscription in English).
93. See Goldman, supra note 74; KNESSET RESEARCH DEPARTMENT,
OVERVIEW, supra note 84.
94. See Steven Erlanger, In a Divided Israel, Angry Words or No Words at All,
N.Y. TIMES, Jan. 7, 2007, http://www.nytimes.com/ 2007/ 01/ 07/ world/ middleeast/
07israel.html.
95. See infra Part III.C.
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the authority to change the Basket, but also the responsibility to make
funds available.96 This power is why the Committee is the only official
gateway for expanding the Basket for the entire Israeli population, and
why funding is expected to come from the public purse, as opposed to• 97
private sources.
Yet, it can be argued that the Committee also grew in stature for
several other reasons: it includes very senior members; it is able to
reach decisions by consensus; and it is willing to take responsibility for
its decisions, heart-wrenching as they might be. None of these traits
are common in Israeli public life, either with public actors or public
institutions." We now turn to some of the criticism leveled against the
Committee due to this emergence.
96. The Israeli Ministry of Finance 2006 budget proposal for the Ministry of
Health claims that the gap between the health insurance premiums collected by
the National Insurance Institute and the full cost of the healthcare basket services
provided by the Kupot Holim is $2.33 billion (of a total expenditure of $5.1
billion). See ISRAELI MINISTRY OF FINANCE, DOCUMENTS CONCERNING THE 2006
BUDGET, available at http://www.mof.gov.il/budget2006/doc/2006.zip (open the file
briyut.pdf, at 60) (document in Hebrew).
97. There were, in practice, at least two other ways to expand the Basket: (a)
while the statute sets a base-level healthcare basket, the Kupot Holim may raise
the bar and has done so, for example establishing funds for 'extraordinary
cases'or; (b) private benefactors have, on occasion, helped pay for medicines that
did not make it into the healthcare basket. Both instances are, in essence, cases of
charity, raising public policy questions. See Zvi Zerahia & Haim Shadmi, Fund
was Established for the Financing of Medications not Funded by the Healthcare
Basket: Moneys will Come from the Kupot Holim, the Ministry of Finance and
Private Donations., HA'ARETZ (Isr.), Jan. 18, 2000, available at
http://www.haaretz.co.il/ arch (article available in Hebrew via subscription ); Roni
Linder-Ganz, The Kupot Holim are not waiting for the Treasury: Will
Independently Expand the Healthcare Basket, HA'ARETZ (Isr.), Dec. 8, 2005,
available at http://www.haaretz.co.il/ arch (article available in Hebrew via
subscription ) (reporting that the KHs, Clalit and Maccabi, announced that they
would provide life-saving medications, including Herceptin, to patients who are
not eligible now. A Health Ministry official was quoted as saiying that such a
move "is enticing in the short run but catastrophic in the long run. The State
should pay for the medications."); Roni Linder-Ganz, Private Fund Will Assist
Patients to Purchase Medications Left out of the Healthcare Basket, HA-ARETZ
(ISR.), July 3, 2006, available at http:// www.haaretz.co.il arch (article available in
Hebrew via subscription ) (assistance for the patients will include the medication
Herceptin).
98. See e.g., Steven Erlanger, Israeli Admits Big Errors in Lebanon War, but
Won't Resign, N.Y. TIMES, Jan. 3, 2007, at A3.
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A. Insufficient Transparency in the Operations of the Committee
The Israeli press has bitterly complained that the public receives too
little information about the Committee and its deliberations, which
were held for quite some time behind closed doors.99 From its
inception, Committee meetings were transcribed, but it decided to stop
doing so in late 2001. The Committee had rational reasons for its
decision, 10 but the timing was troubling. It was at a time when an
Israeli court was deliberating Ha'aretz newspaper's administrative
petition to have the transcriptions revealed.'0 ' Several months later, in
a decision heralded as a major step in the advancement of
transparency of the government, 2 the Jerusalem District Court
mandated that the Ministry of Health provide Ha'aretz its protocols. 03
99. The Ministry of Health's website provides limited information on the
Committee and its workings, and this body does not have its own webpage; there
is, however, information on how to submit proposals to the Committee and on its
decisions regarding basket expansion. In addition, there is an ombudswoman who
hears complaints relating to the 1994 Act, and her website contains a good deal of
information on the application of the 1994 Act. See Miriam Seibzehner & Osnat
Luxenburg, Isr. Ministry of Health, The Adoption of New Medical Technology by
the Israeli National Health Insurance Law (2005), http://www.health.gov.il/
english/ pages-e/ default.asp? pageid=29& parentid=24& catid=14& maincat=2.
See also ISR. MINISTRY OF PHARM. HEALTH, supra note 83 (giving the more
technical requirements for submission into the Basket).
100. See Haim Shadmi, No More Minutes from Health Basket Meetings,
HA'ARETZ (Isr.), Dec. 5, 2001, at http://www.haartz.co.illarch (article available in
Hebrew via subscription) The committee explained that transcription is expensive
and that by the time the transcript is prepared, it is no longer useful to the
committee. Apparently the committee also decided that its members maintain
secrecy during deliberations to prevent outside pressure.
101. See id.
102. The Israeli Freedom of Information Law was only enacted in 1998. See Isr.
Police, Freedom of Information Law, 5758, 1998, http://www.police.gov.il english/
InformationServices/ Law/ xx_5759_1998.asp (last visited Jan. 12, 2007).
103. CA (Jer) 295/01 Ha'aretz v. Freedom of Information Supervisor, the
Ministry of Health, [2002], available at http://www.nevo.co.il/ psika word/ minhali/
mm01295.doc (document in Hebrew). The Israeli appellate court decided that
names of speakers in past protocols be deleted, as such speakers did not anticipate
that the protocol be made public. See Moshe Reinfeld, The Court Ordered the
Exposure of the Healthcare Basket Committee's Meetings, HA'ARETZ (Isr.), Apr.
16, 2002, available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription). See also Ze'ev Segal, The Limits of Censorship During Wartime,
HA'ARETZ (Isr.), Apr. 16, 2002 available at http:www.haaretz.com/ hasen! pages/
arch/ ArchBuyArt.jhtml (article available via subscription in English) (discussing
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While the value of the bare protocols to the medical layman is
debatable, there was, initially, a logical and legitimate purpose in
keeping the deliberations closed. However, there is a compelling
public interest in publicizing the Committee's operations.
In this vein, it is good to see that the Committee has begun to
operate in a more transparent manner. Yet there are still shadows in
this sunshine. As in other aspects of the Committee's operation, it is
probably best to have the matter of the Committee's transparent
operation decided in a clear, formal, and orderly manner.104
B. The Committee Membership
For quite some time there have been critiques of the Committee's
structure. Specifically, it is alleged that the Committee is dominated
by representatives from the government and Kupot Holim. This, in
turn, brought about innuendos of unscrupulous dealings and
suggestions that even if there is no outright corruption, the
government and the healthcare providers still have, as one reporter put
it, "economic interests that do not always fit with the public good."'0'
There appears to be three explanations as to how the Committee
membership was eventually structured. Initially, the Committee was
set up as an advisory body to the government. 0 6 It gained stature to
become the national decision maker regarding Basket expansion. In
theory, however, the Israeli parliament, the Knesset, could bypass the
Committee by establishing another health services advisory board
before passing its budget. Second, the experts on the needs of the
Israeli healthcare market are the managers of the HKs and the
the Israeli judicial system's treatment of media coverage of the government in
relation to national security).
104. See Ran Resnick, What Does the Committee Have to Hide from the Public?,
HA'ARETZ (Isr.), Mar. 30, 2006, available at http://www.haaretz.co.il/arch (article
available in Hebrew via subscription). From 2001 to 2006 the committee did not
transcribe its meetings, but only had summaries made, and they too were not made
public. In 2006, Committee Chairperson Shani reinstituted the transcribing. At
the same time, the Committee meeting of March 29, 2006 was closed to "nosy"
reporters, and only at the insistence of the press did the government reopen the
doors. See also Haim Shadmi, Would it Not Be Better at This Point to Say "Stop",
HA'ARETZ (Isr.), Oct. 19, 1999, available at http:www.haaretz.com/ hasen/ pages/
arch/ ArchBuyArt.jhtml (article available via subscription in English) (the
published minutes of the of the Committee's Febuary 1999 meeting showing how it
was decided not to include the drug Herceptin in the Basket).
105. See Shadmi, supra note 77.
106. See supra p. 17.
2006]
Journal of Contemporary Health Law and Policy [Vol. XXIII:9
Ministry of Health. Their professional opinions must represented or at
least heard by the Committee. Finally, the Committee includes public
representatives, as they should be present to ensure the Committee
proceeds in good faith on behalf of the people.
Including public representatives in the process is, however, not
problem-free. Legitimacy is one concern. While many public
representatives on the Committee are persons of high public standing,
there is no senior judicial officer among them. Israelis tend to trust
public committees more when headed by judges, active or retired.
Some of the public representatives are retired health officials. This
occurrence, depending on one's faith in government, can be either
troubling or reassuring.'0 9 Furthermore, if the idea of democratic
representation is to be given credence, there is unease in the fact that
various groups are not directly represented in the Committee, namely
the poor, the elderly, the Arab-Israeli population, and even women.11
107. See Haim Shadmi, Whom do the Public Representatives Represent?,
HA'ARETZ (Isr.), Feb. 14, 2002, available at http://www.haaretz.co.il/arch (article
available in Hebrew via subscription) ("The committee does not include a retired
Supreme Court Justice or former Cabinet Ministers...").
108. See Zeev Segal, The Power to Probe into Matters of Vital Public
Importance, 58 TUL. L. REV. 941, 944-945 (1984).
Therefore it seems justified to examine the Israeli Law as a good,
although not perfect, example of placing the power to probe into matters
of vital public importance in the hands of an independent quasi- judicial
commission... Many observers, both within Israel and abroad, welcomed
the establishment of this independent, quasi-judicial commission.
Id. at 944-945.
109. On the one hand, they are senior, seasoned professionals; on the other
hand, they are likely to be deeply committed to the government line or, depending
on their current position, to the interests of their current employer (most often
KHs and pharmaceutical industries).
110. See Haim Shadmi, Medicine by Committee, HA'ARETZ (Isr.), Feb. 2, 2002,
available at http:www.haaretz.com/ hasen/ pages/ arch/ ArchBuyArt.jhtml (article
available via subscription in English).
[The Committee], which decides on the fate of millions of people, does
not include a philosopher or clergyman specializing in issues of ethics and
morality. There is no former Supreme Court justice or attorney general,
as on most public committees. Indeed, there are no top-ranking lawyers.
. N]either is there a former minister from one of the social ministries...
Nor is there a professor or senior manager from the field of social work -
or for that matter, anyone from a consumers' group. There is no
representative from the development towns, Russian immigrants, or the
Arab community, even though each one of these communities has special
medical needs.
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While the Committee was seen as merely an internal body of the
Ministry of Health, such arguments seemed minor. This is no longer
so, as the Committee became the main discretion-bearing, decision-
making body on Basket expansion.
Another set of complaints is that public representatives either do not
fully understand the discussion, feel excluded in the deliberations, or
feel that they carry little weight. As the Israeli press has portrayed the
membership, the Committee "serves as a rubber stamp for the Health
Ministry and the HMOs ... [while also containing] political appointees
whose credentials for serving on the committee are in doubt. ' ..
There is a simpler, less insidious explanation for the frustration felt
by many towards these public representatives: the Committee is a
m6lange of two different forums. A highly professional technology
committee brings into account technical and economic considerations
while a public forum makes policy decisions. For the most part, the
Committee wears the former hat, and the "real deliberations are
managed by doctors and economists. The role of the public
representatives on the Committee is to ensure that no irrelevant
considerations be brought."1 "2
Id. The Israeli committee has long deliberated as to whether to include the breast
cancer drug Herceptin in the Basket. The fight over the provision of this drug in
various countries - including England - is well worth a paper in its own right. One
of the accusations of women's organizations in Israel is that the committee is male
dominated and women's representation should be increased to 50%. See Haim
Shadmi, Women's Groups Outraged After HMOs Drop Breast Cancer Drug,
HA'ARETZ (Isr.), Nov. 22, 1999, available at http://www.haaretz.com/ hasen/ pages/
arch/ ArchBuyArt.jhtml (article available via subscription in English). See also
Kamir Orit, Women's Lot is Very Little, HA'ARETZ (Isr.), Feb. 2, 2005, available at
http://www.haaretz.com/ hasen/ pages/ arch/ ArchBuyArt.jhtml (article available
via subscription in English) ("Hence it comes as no surpise that much of the
information about the discrimination against women in Israel is hidden from the
public as well as organization that seek to promote the welfare of women."). See
generally Women Fighting for Herceptin, http:// www.fightingforherceptin.org.uk
(last visited Nov. 19, 2006) (the website of a British advocacy group that wants
Herceptin to be distributed more widely).
111. Shadmi, Medicine by Committee, supra note 110.
112. See Dan Michaeli, The Frustrations of the Public Representatives,
HA'ARETZ (Isr.), Feb. 14, 2002, available at http://www.haaretz.co.illarch (article
available in Hebrew via subscription) (Prof. Michaeli is also a former Director
General of the Health Ministry and, in 2002, was Chairperson of the Board at
Clalit Healthcare Services, a KH).
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C. Public Choice Run Amok
It is difficult to imagine the intensity of pressures placed upon the
Committee and its members from politicians, interest groups, private
individuals, the press, and others. It is not surprising that these
pressures may have changed the Committee's character and brought it
to the verge of explosion."
Public pressure is an obvious occurrence. The Israeli public has
shown great interest in the life-and-death decisions of the Committee.
As previously observed, politicians have realized the public sympathy
for any increase in the budget allocated to the Committee. There are a
significant amount of potential dividends in supporting such increases
(even if only relatively small sums of money are secured) with very few
political risks.1 4 Politicians have quickly caught on to this trick, as the
media keeps reporting their efforts to increase Basket funding." 5
The government at large also adopted this insight. In the past
decade, minister after minister passed along the Health Ministry's
portfolio. These ministers, whether from the political right, left, or
center, supported significant increases in the budget for the Committee
113. On the pressures committee-member are under, see e.g., Shani, supra note
91. The Committee chairman noted how painful it was to read
The letters from children who were fighting to add 20 centimeters to their
height so that they would not be 'dwarfs.' (One boy in sixth grade wrote
to tell me that the children in the school call him and his brother who is in
third grade 'the twins,' because he is so short.)
Id.
114. Attacking the miserly Treasury has always been a popular choice for
politicians; doing so for the sick and infirm - even more so! The problem for
politicians is to get the press to name them as the originators of the budget
increase.
115. This reached the point where politicians' efforts began to look slightly
disingenuous. An example of this is when 86 of 120 Knesset members petitioned
the Prime Minister to place the drug Herceptin in the healthcare basket. Surely
such a majority could have legislated the extra budget on its own. See Zvi Zrahiya,
86 M.K.s Want to Include Drug for Breast Cancer in Basket, HA'ARETZ (Isr.), Nov.
4, 1999, available at http://www.haaretz.com/ hasen/ pages/ arch/ ArchBuyArt.jhtml
(article available via subscription in English); Ran Reznick & Zvi Zrahiya, Health
Gets NIS 350m Boost, at Next Year's Expense, HA'ARETZ (Isr.), May 30, 2006,
available at http://www.haaretz.com/ hasen! pages/ arch/ ArchBuyArt.jhtml (article
available via subscription in English) (Prime Minister Olmert announcing an
increase in the Basket's budget for drugs, including Herceptin).
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while all coming up short-handed. In the end, however, they appeared
with the most saintly image!1
6
The happenings at the Committee and the constant shortage of
funds available to it provide ammunition for ideological critics of
government policy. "The process of establishing the extent of the
healthcare basket and its content," stated one critic, "is further
evidence of Israel's becoming - like the big brother in the United
States - a state where jungle rules apply and only the strong survive."".7
The Treasury has been accused of intentionally undermining the 1994
Act's social intentions, out of "an ideology that is contrary to the spirit
of the Act and advocates privatization." If steps are not taken to
reverse this course a reporter warned, "the inequality in the healthcare
system is likely to rise.",1
8
Interest groups are another source of pressure. Committee members
face two very formidable types of interest groups."9  The first is
patients' associations and their supporters. While most citizen groups
find it difficult to organize, raise funds, and lobby effectively for their
causes, patient associations are the exception. The severity of the
ailments and the intensity of the suffering bring patients, families, and
supporters together. The numerous associations existing in Israel
allow patients to seek counsel, comfort, and support. They often have
the organization needed to launch successful public campaigns. 20 In
116. See, e.g., Haim Shadmi, Two More Medicines were Placed in the Basket
after Barak Intervened, HA'ARETZ (Isr.), Jan. 29, 2001, available at
http://www.haaretz.co.il/arch (article available in Hebrew via subscription) (Prime
Minister Barak, filling in for the Minister of Health, convinced the government to
approve two more drug - one against breast cancer, the other against child
respiratory infections).
117. Beni Moses, Enlightened Democracy and the Healthcare Basket, HA'ARETZ
(Isr.), Mar. 25, 2005, available at http://www.haaretz.co.il/arch (article available in
Hebrew via subscription) (noting that infant mortality rate in the US, despite its
high spending on healthcare, is higher than those of Cuba and 41 other states).
118. Roni Linder-Ganz, Unhealthy Privatization, HA'ARETZ (Isr.), Aug. 24,
2005, available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription). See also Barbara Swirkski, Hatim Kanaaneh & Amy Avgar, Health
Care in Israel, 9 THE ISRAEL EQUALITY MONITOR (Adva Center, Tel-Aviv, Israel),
Nov. 1998, at 25-29, available at http://www.adva.org/ health98_eng.pdf# search=%
22co% 20payments% 20medical% 20healthcare% 20israel% 200ECD% 22
(discussing privatization of health services in Israel).
119. This is said setting aside the interests of the dominant members of the
committee: members from the Ministry of Health and the KHs; the latter are a
formidable interest group in their own right.
120. See infra notes 123-24.
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2005, cancer patients, along with the Israel Cancer Association,
demonstrated in front of the Prime Minster's office during cabinet
deliberations over the Committee's request to increase funding.121 In
2006, colon cancer patients went on hunger strike in front of the
Knesset.122 Patients also find other outlets for support and sympathy,
as their message can resonate throughout the Israeli Medical
Association and the press, who let them voice their grievances '13 or
present their case, 24 sometimes overstepping the line .
121. See Ran Resnick, Cabinet to Discuss Increasing Health Basket Funds
Today, HA'ARETZ (Isr.), Mar. 21, 2005, available at http://www.haaretz.com/ hasen/
pages/ arch/ ArchBuyArt.jhtml (article available via subscription in English).
122. Committee Chairman Shani stated that the additional cancer drugs were
not the Committee's priority, and would not be included in the Basket even if their
budget increased. Nonetheless, the government appropriated an additional $78
million and the Prime Minister requested the committee to approve the cancer
drugs. See Ran Rezink, Medical Decisions Based on Political Considerations,
HA'ARETZ (Isr.), May 30, 2006, available at http://www.haaretz.co.il/arch (article
available in Hebrew via subscription). The Prime Minister was criticized for not
handling the pressure and failing to explain that many of the government's
budgetary decisions impact peoples' lives. See Nehemia Stressler, Cheese Giving
Holiday, HA'ARETZ (Isr.), June 1, 2006, available at http://www.haaretz.co.il/arch
(article available in Hebrew via subscription).
123. See e.g., Irit Inbar, What Are 5 Million Shekels of 667?, HA'ARETZ (Isr.),
June 29, 2006, available at http://www.haaretz.co.il/arch (article available in
Hebrew via subscription) Chairperson of the Israeli Osteoporosis and Bone
Disease Association stating in an op-ed:
[T]he members of the healthcare basket committee are meeting to decide
about the final medications to enter the basket. Many patients will
demonstrate in front of the government offices and sound their voice. Yet
there is a group of about 300 people whose members cannot go out and
demonstrate and they do not have a strong enough lobby in government.
These are the elderly osteoporosis patients that only one medication can
today save...
Id.
124. See Haim Shadmi, Lobbyists At Work, HA'ARETZ (Isr.), Jan. 27, 2000,
available at http://www.haaretz.com/ hasen/ pages/ arch/ ArchBuyArt.jhtml (article
available via subscription in English) (In sympathizing with the misfortune of
groups that do not have the ability to organize and lack the political clout to have
"their" medicines added to the Basket, the reporter mentions a medication for the
treatment of Alzheimer that was added because of a strong lobby. The reporter
also noted that additional medications entered for this reason while others, that
should have been included, were left out because there was no one to promote
them).
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The second interest group is the pharmaceutical industry, a lobby
that is well organized and financed. This industry is notorious for its
aggressive and competitive lobbying practices directed at both medical
practitioners and legislators. 26 The industry is seeking to promote its
products with the Committee for one major reason: there is a good
deal of money on the table. The medications being purchased are
typically the most expensive, most modern, and most innovative.'
7
Furthermore, it is not just the Israeli pharmaceutical industry battling
for the Committee's attention; the entire international pharmaceutical
industry is pressing for products to be included in the Israeli Basket.
2 8
Most criticism focuses on the influence exerted by the
pharmaceutical companies to have their products brought before the
Committee and approved for use. Their influence stems from their
familiarity with the Committee members with whom they work on a
daily basis. The pharmaceutical industry also applies their influence
on the other power-broker, the patients' lobby,29 using what seems to
some as underhanded tactics.'30 On the issue of deceitful practices, a
125. Ha'aretz reporter Benni Zipper severely criticized television reporter
Emanuel Rosen's story on the Basket as a a cheap demagogy that is unbalanced
and tainted with kitsch-effects. Benni Zipper, TV This Week, HA'ARETZ (Isr.),
Mar. 24, 2002, available at http://www.haaretz.co.il/arch (article available in
Hebrew via subscription).
126. Cf Jim Drinkard, Drugmakers Go Furthest to Say Congress, USA TODAY,
Apr. 25, 2005, at 1B, available at http://www.usatoday.com/ money/ industries/
health/ drugs/ 2005-04-25-drug-lobby-cover.x.htm) (noting a similar dynamic with
the pharmaceutical industry in the US); UNITED KINGDOM PARLIAMENT, SELECT
COMMITTEE ON HEALTH, REPORT, 2004-5, H.C. 42-I1, at app. 26, available at
http://www.publications.parliament.uk/ pa/ cm200405/ cmselect/ cmhealth/ 42/
42we30.htm (noting a similar dynamic with the pharmaceutical industry in the
UK).
127. See supra note 122 and accompanying text.
128. See e.g., Pharma Israel - The Association of the Research Based
Pharmaceutical Companies, http://www.pharma- israel.org.il/ eng/ Htmls/
article.aspx? C1004=582& BSP=573 (last visited Jan. 15, 2007) (explaining the
advocacy group's mission to represent multinational pharmaceutical companies in
dealing with the Basket and its process.).
129. See Haim Shamdi, The Companies Give Money - and the Patients'
Associations Pressure for the Drugs to be Included in the Healthcare Basket,
HA'ARETZ (Isr.), Dec. 24, 2001, available at http://www.haaretz.co.il/arch (article
available in Hebrew via subscription).
130. Haim Shadmi, The Road to the Healthcare Basket is Paved with Threats,
Pressures, Snitching and Dirty Trickery, HA'ARETZ (Isr.), Jan. 28, 2002, available at
http://www.haaretz.co.il/arch (article available in Hebrew via subscription)
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common complaint that resonates with public opinion is the direct
corruption of Committee members. It is safe to say that most Israelis
believe their elected politicians are corrupt, a common concern for
most countries.
31
In the first few years following its inception, the Basket Committee
was treated by the press and the public with respect befitting the
seniority of its members and the gravitas of its mandate. In recent
years, as the Committee's public profile increases, its function becomes
more politicized, and the economic ramifications of its operation
become clear, Committee membership has been beset by allegations of
misconduct. Among the charges have been unreported potential
conflicts of interests 32 and receipt of gifts from pharmaceutical
companies.'33 A seminar held at Jerusalem's Hadassah University
Many means are kosher in the eyes of the pharmaceutical companies in
the competition over the profitable place in the healthcare basket.
Novartis, for example, threatened to stop provision of the Gleevec
medication freely provided to 100 leukemia patients, or as a senior Health
Ministry official defines it - 'shut down their faucet of life.' The threat
helped and the medication got into the basket. Other means: signing
politicians on petitions, funding a SHAS [ultra-orthodox political party]
convention, snitching to the Ministry of Health and payment to MD for
recommendations.
Id.
131. See e.g., Press Release, The Israel Democracy Institute, The Israeli
Democracy Index 2006: Only 17% of the Israeli Public Believes that Politicians
Keep their Promises after Elections (2006), available at http://www.idi.org.il/
english/ article.asp? id=01052006145754 (Israeli perceptions of politicians; entire
report available in .pdf format). But see TRANSPARENCY INT'L, CORRUPTION
PERCEPTIONS INDEX 2005 (2005), http://www.transparency.org/ policyresearch/
surveys-indices/ cpi/2005 (showing Israelis as not perceiving too much corruption
in their government, especially when compared to other nations).
132. Ran Reznik, Dr. Brelovich, Member of the Healthcare Basket Committee,
Did Not Publicly Announce to the Committee That His Wife Works for Merck
Pharmaceuticals, HA'ARETZ (Isr.), Sept. 1, 2005, available at
http://www.haaretz.co.ii/ arch (article available in Hebrew via subscription).
Committee member, Dr. Goldman, was not aware that Mrs. Berlovich, the wife of
the Associate Director General of the Ministry of Health, had been employed by
Merck for 8 years. The company's products are often considered for inclusion in
the basket by the committee. Id.
133. Senior officials of the healthcare system and some members of the
Committee, such as Dr. Blashar, were invited to speak at a conference in St.
Moritz, Switzerland. To cover their expenses, conference organizers received
donations from Johnson & Johnson. See Ran Reznik, Placing the Holiday Before
the Medication, HA'ARETZ (Isr.), Dec. 7, 2001, available at http://www.haaretz.co.il/
Regulating Life and Death
Hospital received great publicity when senior professors in attendance
declared that the struggle over inclusion of medications in the Basket
is replete with bribery and favoritism.
1 34
Stepping back, another look should be given to this issue, beginning
with these misconduct allegations. The cases just mentioned are
isolated, almost petty. Additionally, there are examples of Committee
members who adamantly refused to receive any benefits from
pharmaceutical companies.35 Furthermore, the Israeli Civil Service
Commission, the agency in charge of employment and discipline for all• 136
civil service employees, has ruled against such practices. The Israeli
Medical Association has contributed by establishing an ethical code for
the relations between doctors and the pharmaceutical industry.3
These are all reasons to believe the situation has improved.
arch (article available in Hebrew via subscription). Pharmaceutical companies
reportedly subsidized $222 for each of the 100 senior physicians at a professional
conference, among them Dr. Berlovich and various other officials. For a detailed
and fairly balanced report, see Ran Reznik, The World's Largest Pharmaceutical
Company Finances Exclusive Hotel for Ministry of Health Official, HA'ARETZ
(Isr.), Aug. 31, 2005, available at http://www.haaretz.co.il/arch (article available in
Hebrew via subscription).
134. See Haim Shadmi, Almost Everything is Bribes, Favoritism and
Connections, HA'HARETZ (Isr.), Jan. 8, 2003, available at http://www.haaretz.com/
hasen/pages/ arch/ ArchBuyArt.jhtml (article available via subscription in
English); Haim Shadmi, Bribery. . . Everyone Know. Everyone is Getting,
HA'ARETZ (Isr.), Apr. 28, 2003, available at http://www.haaretz.com/ hasen/ pages/
arch/ ArchBuyArt.jhtml (article available via subscription in English) (explaining
that the healthcare basket expansion committee denounces the accusations
mentioned). Surprisingly, Committee member Rabbi Yoseph Zvi Ben Porat,
when asked whether the trips and goods given by the companies were bribes,
replied "Of course [they are] ... because for money, people will do anything." Id.
135. See Ran Resnik, Instead of Rating the Medications, the Healthcare Basket
Committee Turned into a Budget Lobbyist, HA'ARETZ (Isr.), Mar. 20, 2005,
available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription)(mentioning that Professor Alexander Aviram, a senior official of
Kupat Holim Maccabi and member of the Committee, refused to meet a
representative of Roche Pharmaceuticals to discuss his criticism of one of their
products).
136. See e.g.,. Ran Reznik, Doctors Receiving Funding from Pharmaceutical
Companies for a Conference in a Hotel are Committing a Criminal Offense,
HA'ARETZ (lsr.), Sept. 2, 2005 available at http://www.haaretz.co.il/arch (article
available in Hebrew via subscription) (concerning an announcement of the Israeli
Civil Service Commission).
137. See Yoram Blashar, No Bribery, No Favoritism, HA'ARETZ (Isr.), Jan. 15,
2003, available at http://www.haaretz.co.il/arch (article available in Hebrew via
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The reason this issue is treated so cavalierly is because the
Committee is clearly not corrupt, in the sense that its conduct or
operation is illegal. The members are too senior and the proceedings
too open. There are valid reasons for public concern over the deep
links between the pharmaceutical industry, the medical profession, and
political power, but the concern should lie in the decisions made
everyday by medical doctors and the influence of private money on
medical research.
138
Moreover, much of the criticism comes from Committee members
who are not familiar with the medical market.'39 Novel medical
products are expensive and their results are often unpredictable; the
number of patients in need of such treatments can be similarly difficult
to assess. 140 Therefore, utilization of new medicines may not be the
most reliable and cost-effective business model. As just mentioned, on
subscription) (explaining that the committee's decision-making process is a marvel
of a public process).
138. See Haim Watzman, Israeli Research Must be Re-directed, 6 NATURE
MEDICINE 9 (2000), available at http://www.nature.coml nm/ journal/ v6/nl/ pdf/
nm0100_9b.pdf ("Israeli doctors are devoting research time largely to clinical trials
for foreign drug companies, an activity that produces no new basic research
knowledge, says Dov Lichtenberg, deputy dean of Tel Aviv University's Sackler
Medical School."). Similar occurrences are found in America as well. See
Marshall B. Kapp, Drug Companies, Dollars, and the Shaping of American Medical
Practice, 29 S. ILL. U. L.J. 237, 241 (2005) ("In 2001, the American pharmaceutical
industry spent $12.5 billion on marketing its products, equaling approximately
$10,000 per licensed physician, a 50% increase since 1998."); Howard L. Dorfman
& Linda Pissott Reig, Avoiding Legal and Ethical Pitfalls of Industry-Sponsored
Research: the Co-Existence of Research, Scholarship, and Marketing in the
Pharmaceutical Industry, 59 FOOD & DRUG L.J. 595 (2004).
The marketing activities of the research-based pharmaceutical industry
have been under intense scrutiny during the past decade as never before.
The Food and Drug Administration (FDA) and other regulatory agencies
have examined every aspect of a drug company's interactions with both
healthcare professionals and the lay public, including promotional contact
between sales representatives and physicians, continuing medical
education, and direct-to-consumer advertising. Another activity
undergoing review is the role of the pharmaceutical company in
sponsoring, conducting, and reporting the results of medical research.
Id. at 595.
139. See Haim Sadmi, Seniors at the Committee Talk As-If to the Ears of the
Pharmaceutical Industry. It's Scary, HA'ARETZ (Isr.), Jan. 30, 2002, available at
http://www.haaretz.co.il/arch (article available in Hebrew via subscription).
140. THE ECONOMIST, An Overdose of Bad News, Mar. 19, 2005, at 73
(discussing the risks involved in developing new drugs).
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the whole, Committee members are deeply acquainted with the
patients, the bureaucracy, the economics of medicine, and the
pharmaceutical industry. The links the Committee has with the
pharmaceutical industry may therefore be advantageous as a source of
experience and outside resources that can help the Committee better
understand this market.
D. The "Funny Economics" of the Healthcare Basket
The economics of the Basket have their peculiarities. The classic
story heard in this context is of a patient who vitally needs a drug; she
cannot afford to pay its full price out of pocket, and then wonders why
the state health insurance won't help.' 4' The answer to her question
involves the cost of the relevant treatment, the limited budget allotted
for annual expansion of the Basket, and the fair and rational decision-
making process that takes place in the Committee. Yet from the
economic standpoint this story has several wrinkles, not obvious to
most:
1. The Price of Innovation
Estimating the precise cost of new drugs, technologies, or
procedures under consideration before the Committee poses a real
difficulty. In general, new products, especially medication, tend to be
very expensive, reflecting research and development costs borne by the
pharmaceutical companies.142  Moreover, there are only educated
estimates of how many patients will need and use such products. 143 In
141. See, e.g., Avital Nitzan, Keeping Level, HA'ARETZ (Isr.), OCT. 30, 2000,
available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription)(relating the story of an anemic cancer patient who needs an
expensive drug, not included in the Basket); Yuval Azoulay, Cancer Patients'
Hunger Strike Continues Outside Knesset, HA'ARETZ (Isr.) May 18, 2006, available
at http:// www.haaretz.com/ hasen! pages/ arch!ArchBuyArt.jhtml (article available
via subscription in English) (protestors wondering why a cancer drug is not in the
Basket with so many afflicted with the ailment).
142. Jonathan P. Glazier, The Drug Price Controversy: A Review of Actions
Taken by the Pharmaceutical Industry and the Federal and State Governments, 1 J.
HEALTH & BIOMEDICAL L. 163, 165 (2004) (stating "a new drug costs
approximately $800 million to introduce into the market. Prices are set in order to
recoup the investment made in these drugs, including research, development,
trials, marketing, etc.") (citations omitted).
143. In 2005, a new psoriasis medication was introduced to the basket at an
annual cost of $1.7 million. Kupat Holim Maccabi and the manufacturer presented
data suggesting that 400 Israeli patients need the medication. The Israeli
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addition, several newspaper reports intimate that perhaps the KHs end
up getting a discounted price for medication.' 44 If such is the case, the
entire cost-structure of the medical services market may be in
question, and may require public intervention. The consequences of
non-disclosure create the suspicion that the KHs are overcharging the
public by requesting co-payments based on the full-price, which raises
the public contribution to financing medical products.
145
2. The economics of co-payments
In a recent petition to the Supreme Court, Justice Rubinstein was
particularly troubled by the co-payment system under the 1994 Act
which requires the insured to make co-payments. He noted that the
co-payments are set at 10% of total cost in most cases, with a minority
payment range oft 25% to 50% and a majority payment range of 70%
Dermatologists estimated the number at 130. The Committee approved funding
for 150 patients. A Ministry of Health internal report apparently suggests that six
months after its approval, the medication was given to only thirty-three patients.
See Ran Resnik, Expanding the Basket Won't Solve the Mismanagement in
Setting It, Ha'aretz (Isr.), Apr. 10, 2006, available at http://www.haaretz.co.il/arch
(article available in Hebrew via subscription); Ran Resnik, The Prime Benefactor
is the Kupa, not the Patients, Ha'aretz (Isr.), Oct. 26, 2005, available at
http://www.haaretz.co.il/arch (article available in Hebrew via subscription); Ran
Resnik, How Much Does Each Medication Cost? The Ministry of Health only
Replies with "Approximately", Ha'aretz (Isr.), Mar. 21, 2005, available at
http://www.haaretz.co.il/arch (article available in Hebrew via subscription) (The
reporter asked for the cost estimates provided to the committee; he was refused
the information and was told by a ministry spokeswoman that "it's all rough
approximations").
144. See Ran Resnik, How Much Does Each Medication Cost? The Ministry of
Health Only Replies with "Approximately", Ha'aretz (Isr.), Mar. 21, 2005,
available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription)(explaining that the manufacturer of the Psoriasis medication told the
Ministry of Health that it sells the drug to KHs at $800 per units-but some of the
KHs claimed to be buying the drugs at $960 per unit).
145. See Haim, How Much do Medications Really Cost the Kupot Holim?,
Ha'aretz (Isr.), Mar. 30, 2001, available at http://www.haaretz.co.illarch (article
available in Hebrew via subscription) (citing a Committee member, calling it "the
best kept secret in the country").
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to 80%. 46 Newspaper reports keep the issue in the public's eye with
stories of how co-payments adversely affect individuals.
47
3. Is this all for real?
Many observers find the entire affair, the enormous efforts taken by
the Committee and the public attention surrounding it, to be a
charade, with the purpose of diverting attention towards the
Committee.18 Nevertheless, the reason is clear: there is simply not
enough money involved. Noted one observer:
Within the array of medications, medical technologies,
operations and treatments that the state finances annually to its
citizens within the healthcare basket - at a cost of [$5.1 Billion] -
this medication is merely a footnote. Its cost is [$1.7 million] and
it was supposed to be given to only about 150 patients.
49
146. It is 70% for treatment of sleep apnea and 80% for artificial limbs, for
example. See HCJ 2974/06 Israeli, at 8-9.
147. For example, a single mother of four cannot afford an ear operation.
Generally, the co-payment for an ear operation is 70% of the total cost, which can
be up to $15,000. See Roni Linder-Ganz, For Free Plus $15,000, HA'ARETZ (Isr.),
Mar. 6, 2006, available at http://www.haaretz.co'il/arch (article available in Hebrew
via subscription) ("the co-payments of the health basket are too high, preventing
the purchase of medication from exactly the people it was supposed to help").
Additionally, a mother of a thirty-two year-old schizophrenic complains about the
increase in the monthly co-payment on her son's medications, from $9 to $75,
because the medications are now included in the healthcare basket. See Haim
Shadmi, The Medication Went into the Government Basket: the Patients Pay More,
HA'ARETZ (Isr.), Apr. 14, 2000, available at http://www.haaretz.co.il/arch (article
available in Hebrew via subscription).
148. See e.g., Eli Shamir, The Basket Is Not All That Matters, HA'ARETZ (Isr.),
Mar. 23, 2006, available at http://www.haaretz.co.il/arch (article available in
Hebrew via subscription) (Professor Shamir, President of OZMA, the Israel
Forum of Families of People with Mental Illness, stating: "We see daily in the
press, the Knesset, the election campaign, how the healthcare basket takes over
the entire health agenda. This [budget] increase is all that matters. Pressures to
increase this basket may block all the vital needs of the healthcare system.").
149. Ran Reznik, The Main Beneficiary Is the Kupa, Not the Patients, HA'ARETZ
(Isr.), Oct. 26, 2005, available at http://www.haaretz.co.il/arch (article available in
Hebrew via subscription). The conversion ratio used by this author hereinafter is
4.5 New Israeli Sequels (NIS) per 1 U.S. dollar. As of October 24, 2006, the
conversion rate was exactly 4.2830 NIS per 1 US Dollar. See Bank of Israel,
Foreign Currency Exchange Rates, http://www.bankisrael.gov.il/ eng.shearim/
index.php? day= 24& month= 10& year= 2006 (last visited Feb. 10, 2007).
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The sums of money involved are so small, and the fuss and public
attention so enormous, that surely we are not looking at regular
appropriations procedures but rather a "show" presented to the public.
Another comment is that the entire budget allotted for the annual
expansion of the Basket only equals the price of two military tanks, not
much at all.150 Such is the case with the entire Basket expansion effort:
there is relatively little money available.' Yet, it is likely that the
government, if convinced by outside pressure, could provide the
increased budget requested by the Committee, even without the public
outcry.' So why is the agonizing process still going on?"'
References to Israeli dollars are clearly marked with "NIS;" otherwise, the amount
is in U.S. dollars and, unless quoted by a source, has been converted by the author.
150. See Haim Shadmi, The National Fiasco of Not Expanding the Healthcare
Basket, HA'ARETZ (Isr.), Feb. 6, 2002, available at http://www.haaretz.co.il/arch
(article available in Hebrew via subscription)(citing Ruth Amir, Chief Instructor at
the National Security College).
151. The national healthcare budget is over NIS 46 billion, while total
expenditures by the government is over NIS 269 billion. ISR. CENT. BUREAU OF
STATISTICS, REVENUE AND EXPENDITURE OF GOVERNMENT, LOCAL AUTHORITIES,
NATIONAL INSTITUTIONS AND GOVERNMENTAL NON-PROFIT INSTITUTIONS 1,
http://wwwl. cbs.gov.il/ shnaton56/ stl4_ 1l.pdf; ISR. CENT. BUREAU OF STATISTICS,
ISRAEL IN FIGURES 2005 15, http://www.cbs.gov.il/ publications/ isrinn05e.pdf.
152. There are three arguments that can be made to convince the government
to increase the Basket budget. First, Israel should follow other western nations
which increase their healthcare budget by 2% per year, rather than maintain its
current practice of increasing the budget by only 1% per year. See Yoram Blashar,
There is Money, There Are No Medications, HA'ARETZ (Isr.), Mar. 19, 2006,
available at http:// www.haaretz.co.il/ arch (article available in Hebrew via
subscription). Second, the government should not distribute any surplus money in
the healthcare budget to other ministries, rather the health system should retain
any surplus. See Haim Shadmi, Health Surplus Will Go to Security Budget,
HA'ARETZ (Isr.), Nov. 11, 2006, available at http://www.haaretz.com/ hasen/ pages/
arch/ ArchBuyArt.jhtml (article available via subscription in English) (discussing
the government's decision to distribute the surplus health budget for 2000 to other
ministries, including the Defense and Public Security ministries). Third, the
government should oversee and limit healthcare spending. For example, the
government is required to, but does not supervise HMO spending on drugs and
technology that is included in the Basket. See Haim Shadmi, Medical Basket
Funds Go to HMO's Operating Budgets, HA'ARETZ (Isr.), Dec. 2, 2002, available at
http://www.haaretz.com/ hasen/ pages/ arch/ ArchBuyArt.jhtml (article available
via subscription in English).
153. In an apologetic op-ed, Committee Chairman Shani explained how
unbearable it is to read letters from the public who are fighting for their own lives
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An obvious answer is that healthcare costs are increasing at an
alarming rate and a gate-keeping mechanism, in this case the
Committee, is likely to be needed for quite some time. Some
government body is necessary to ration public funds, even if such funds
are a fraction of the true cost of modern healthcare. Moreover, the
Committee's decisions to add medications, procedures and
technologies are accruing, with no decline in what medications,
procedures and technologies remain in the Basket.14 Simply put, more
tough decisions need to come to the Committee.
Yet, as many observers remark, the Israeli government must
establish and maintain two crucial elements that are currently lacking.
First, the government and the Knesset need to allow an automatic
update of the Basket's total value at a rate of 2-4%."'5 Second, as
various distinguished members of the Committee have pointed out:
Israel needs to establish a clear national healthcare policy.
There [is a] need to decide about priorities. Facing the
technological policy that will establish the most benefit for the
general public will stand the private individual with his varied
ailments. Some of the patients will not be provided with
innovative treatments and they will have to make-do with the
conservative basket . . . In the medical and bio-technologically
oriented medical world that we are living in, the scarcity will
only increase. Only a clear health policy, combining examination
of the individual patient's need and society's involvement in the
decision-making process, will strengthen health as one of the
foundations upon which society is built and will improve health
in Israel.'56
or for the lives of their relatives. See Shani, The Heart of the Health-Basket, supra
note 91.
154. Indeed, it is possible that some of these medications have become
redundant and should be removed from the healthcare basket, bringing about
millions in savings. See Shadmi, The National Fiasco of Not Expanding the
Healthcare Basket, supra note 149.
155. See e.g., Roni Linder-Ganz, The Remedy for Cancer Patients: Automatic
Update of the Healthcare Basket, HA'ARETZ (Isr.), Mar. 27, 2006, available at
http://www.haaretz.co.il/ arch (article available in Hebrew via subscription).
156. Shuki Shemer, What Will Enter the Basket, HA'ARETZ (Isr.), Dec. 9, 1999,
available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription). At the time, the author, Prof. Shemer, was the Director General of
the Health Ministry. He is currently Director General of Maccabi Healthcare
Services. See also supra note 105 and accompanying text. Prof. Michaeli, also a
former Director General of the Health Ministry and in 2002 a former Chairperson
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Such a policy, conducted with long-term thinking in mind, could
bring about a significant increase in healthcare expenditure. This
course of action would improve Israelis' quality of life, resulting in
reductions in sick-leave, hospitalization bills, and disability pensions."'
Unfortunately, such changes are unlikely to take place in Israel in
the near future. While the first recommendation, an automatic update,
is sound public policy,11s it is essentially against all political interests.
The Treasury wishes to retain its control over the budget, and
politicians realize the huge political capital they can gain by securing
additional funds for the Committee. As for the second recomendation,
the political instability of the country coupled with a high turnover of
Health ministers make it unlikely that a serious national policy
deliberation will take place any time soon. 9  Such conditions
demonstrate why the annual debate over the rising costs of the
Basket's services has the potential to develop into an exciting ritual,
not to be missed by participants or spectators.
E. How the Committee Has Become a Player in its Own Right
In March 2005, the Committee, headed by Dr. Bolislav Goldman,
took an unprecedented step in refusing to rank medications according
to their importance and usefulness.' 60 Rather, the Committee
presented all of its recommendations for fifty-five new medications,
technologies, and examinations en-bloc. The total costs proposed
amounted to 465 million New Israel Sheqel [NIS]; the government
only budgeted a mere NIS 200 million.16 ' Advocates for this budgetexpansion claimed that the government needs to take more
of the Board at Clalit Healthcare Services, called for the establishment of a
committee that would define the targets of the Israeli healthcare system.
157. See Shadmi, The National Fiasco of Not Expanding the Healthcare Basket,
supra note 149.
158. So much so, that Prime Minister Olmert's government stated as its main
health policy goal to adopt "a policy of a measured and appropriate enlargement
of the health basket. Beginning in 2007, the drug basket will increase by 4% per
annum.. ." ISR. PRIME MINISTER'S OFFICE, GOV'T POL'Y, para. 33,
http://www.pmo.gov.il/ PMO/ Government/ Policy.
159. See Zvi Zerahia, The Knesset Rejected Proposal to Establish a Committee to
Examine the Medication Crisis, HA'ARETZ (Isr.), June 1, 2006, available at
http://www.haaretz.co.il/arch (article available in Hebrew via subscription).
160. See infra note 165.
161. See Ran Reznick, Cabinet to Discuss Increasing Health Basket Funds
Today, HA'ARETZ, Mar. 21, 2006, available at http://www.haaretz.co.il/ hasen/
pages/ arch/ ArchBuyArt.jhtml (article available via subscription in English).
Regulating Life and Death
S • • 162
responsibility over its life-and-death decisions. 2 Even though an
increase of NIS 70 million was approved by the Finance Minister,' it
can be said that the Committee has shirked from carrying out its basic
function. There is merit in the claim that it has turned into yet another
lobby for an increase of the Basket's budget. At the same time, by
entering the political budgetary field, the Committee enhanced the
public pressure on the government, which has worked as recently as
2005.'64
In March 2006, the Committee again recommended new drugs and
technologies for a price of NIS 104 million, though the government had
initially approved only NIS 37 million. Again, the Committee correctly




The political nature of the Basket became clear during the 2006
general elections."' Israeli State Attorney General Menahem Mazuz
162. See id.
163. Id.
164. See id. Moti Bassok, 150 Million Shekels for the Healthcare Basket Will Be
Transferred Immediately After the 2005 Budget is Approved, HA'ARETZ (Isr.), Mar.
25, 2005, available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription) (Prime Minister Ariel Sharon and Treasury Secretary Benjamin
Netanyahu came to an agreement on an additional budget for the healthcare
basket).
165. The 2006 Committee is headed by Prof. Mordechai Shani, who reportedly
said the members considered resigning and returning their mandate to the
government, given the inadequate funding. See Ran Reznick, The Healthcare
Services Basket Committee Demand 467 Million NIS for New Medications,
HA'ARETZ (Isr.), Mar. 30, 2006, available at http://www.haaretz.co.il/ arch (article
available in Hebrew via subscription); Ran Reznick, Moti Bassok & Nir Hasson,
Compromise: 310 million Shekels Worth of Medications Have Been Added to the
Basket, HA'ARETZ (Isr.), Apr. 10, 2006, available at http://www.haaretz.co.il/ arch
(article available in Hebrew via subscription); Ran Reznick & Zvi Zerahia, Health
Gets NIS 350m Boost, at Next Year's Expense, HA'ARETZ (Isr.), May 30, 2006,
available at http://www.haaretz.co.iU hasen/ pages/ arch/ ArchBuyArt.jhtml (article
available via subscription in English); Ran Reznick, Ten More Medications Will
Enter the Healthcare Basket Starting July 1, HA'ARETZ (Isr.), June 19, 2006,
available at http://www.haaretz.co.il/arch (article available in Hebrew via
subscription) (an additional 157 million NIS are added as the government accepts
the Committee's budgetary demands). See also Shadmi, Panel Opposes New
Antibiotics for Health Basket, supra note 86 (noting, in 2001, that the Committee
has never had its recommendations for budget increases denied).
166. Already in late 2005 there was concern in the health system that early
elections might delay the passing of the national budget and therefore the
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instructed the Committee to postpone its final decisions, as opposed to
its deliberations, for two weeks so they would come after election day.
This move was part of his policy allowing the interim government to
only make such decisions as were essential for the day-to-day running
of government. 16  It is possible that the Attorney General was
concerned that Committee decisions would be used as part of the
election campaign.
. The End-Run?
The increased political tension around the Committee's operation
now seems likely to bring about a major overhaul. There have been
various indications that the Committee is losing its professional
decision-making autonomy. Recent pressure by the Prime Minister on
the Committee to approve cancer drugs demanded by colon cancer
patients is one indicator. The Committee has not made a decision,
but some sources find it likely that the Committee will cave in to such
pressures, or accept some sort of deal with a significant budgetary
increase. Should this happen, the cancer patients will have won their
public struggle but at the price of politicizing the process.16' Health
budgeting of additional funds for the Basket. See Roni Linder-Ganz, Former
Health Ministers to the Treasury Secretary: Transfer 400 Million Shekels for the
Upcoming of the Healthcare Basket, HA'ARETZ (Isr.), Dec. 5, 2005, available at
http://www.haaretz.co.ill arch (article available in Hebrew via subscription); Zvi
Zerahia, The [Knesset] Finance Committee Demands an Increase of the Healthcare
Basket Budget by 350 Million Shekels, HA'ARETZ (Isr.), Dec. 14, 2005, available at
http://www.haaretz.co.il arch (article available in Hebrew via subscription).
167. A petition to the Supreme Court against the Attorney General's decision
was rejected. See Zvi Zerahia, Ren Reznick & Yuval Yoaz, Attorney General
Mazuz: The Healthcare Basket Should not be Decided Before the Election,
HA'ARETZ (Isr.), Mar. 16, 2006, available at http://www.haaretz.co.il/ arch (article
available in Hebrew via subscription). The Supreme Court rejected the petitions
in a 2 to 1 decision. HCJ 2453/06 Israeli Medical Association v. Attorney General
[2006] IsrSC, available at http://elyonl.court.gov.il/ files /06 /530 /024 /o04
/06024530.o04.pdf (document in Hebrew).
168. Meirav Arlozorov, Everything's Politics, Even Human Lives, HA'ARETZ
(Isr.), May 22, 2006, available at http://www.haaretz.co.il/arch (article available in
Hebrew via subscription) (the principle one can deduce from Olmert's capitulation
to the strikers' is that in Israel he who presses more gets more, and there is no
room for professional judgment in the running of the state, only room for politics).
169. See Ran Reznik, Medical Decision for Political Reasons, HA'ARETZ (Isr.),
May 30, 2006, available at http://www.haaretz.co.il/ arch (article available in
Hebrew via subscription); Arlozorov, Everything's Politics, Even Human Lives,
supra note 168. See also Editorial Staff, Main Editorial, HA'ARETZ (Isr.), May 23,
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Minister Yacov Ben-Yizri set another troubling precedent when he
announced the move of NIS 3.3 million from the Committee's budget
to pay for medications the Committee previously rejected. The press
blamed the Minister in succumbing to public and political pressures
and this step seriously undermines the work of the Committee.7'
Finally, the political pressures on the Committee brought them into
direct confrontation with the current Prime Minster, risking a potential
overhaul of the Committee's membership and work.
The Prime Minister, Mr. Olmert, had openly criticized the
Committee's operation and demanded the appointment of a new
Committee with a radically changed composition. Olmert's demands
include a reduction in the Committee's size (from twenty-five to
fourteen members) and the inclusion of four law and ethics specialists,
four economists, four retired healthcare specialists and one
representative each from the Ministries of Health and Treasury.'
This means there will be no members of the KHs, no active medical
doctors, and no members of the Israeli Medical Association on the
Committee. The proposed changes are apparently the result of claims,
as outlined above, that current Committee members have possible
conflicts of interests. It is important to note that under the new
scheme proposed by the Prime Minister there will be two new advisory
committees to assist the principal body: a medical committee including
active doctors, heads of the KHs and the Israeli Medical Association,
and an economic committee.
172
2005, available at http://www.haaretz.co.il/ arch (article available in Hebrew via
subscription). As noted, senior politicians have tried to influence the Committee in
the past, but it's now seen as a political move to woo voters, not help the poor.
170. See Ran Reznik, Tough Questions Regarding the Minister's Functioning,
HA'ARETZ (Isr.), May 26, 2006, available at http://www.haaretz.co.il/arch (article
available in Hebrew via subscription).
171. See Ran Reznik, Olmert Demands a New Committee for the Healthcare
Basket - Without Active MDs, HA'ARETZ (Isr.), June 9, 2006, available at
http://www.haaretz.co.il/ arch (article available in Hebrew via subscription).
172. See id.; Ran Reznik, Ten More Medications Will Enter the Healthcare
Basket Starting July 1, HA'ARETZ (Isr.), June 19, 2006, available at
http://www.haaretz.co.il/ arch (article available in Hebrew via subscription). The
Sharon government decided that the Committee will have twelve members, none
of whom are public representatives. It would have three members from the
Ministry of Health, one from the Treasury, six doctors and two health-economists.
Shahar, 270 New Political Appointments, supra note 79.
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G. A Final Word.
The CEO of Clalit Health Services Group, Ze'ev Wormbrand, nicely
summarizes the state of the Israeli healthcare basket:
[o]ur healthcare basket is the most advanced in the world. We
approve medical technologies well before other countries. For
example, dialysis is not provided in England for persons older
than 65. With us, an elderly 88 year old can receive dialysis
treatment. After all, the value of life here is greater.
7
1
Moreover, budgeting is clearly a political issue. The Basket is only
one of the many services in Israel's waning welfare state. Limited
government funds have to cover education; welfare for the young, the
elderly, the disabled and unemployed; national security, and all the
other obligations of statehood. On a more optimistic note, we now
move on to a short discussion of one of the unique budgeting priorities
of the Israeli national healthcare system: fertility treatments.
IV. REGULATING LIFE: FERTILITY TREATMENT IN ISRAEL
A. Public Financing of ART: An Introduction
The United States and Israel are widely regarded as possessing
two of the most ART [Assisted Reproductive Technology]-
friendly environments in the world. Both countries stand at the
epicenter of fertility-related research and practice and support
the supply and demand sides of the ART market with avidity.
1 74
173. Meirav Arlozorov, After All, the Value of Life in Israel is Greater,
HA'ARETZ (Isr.), March 21, 2006, available at http://www.haaretz.co.ill arch (article
available in Hebrew via subscription). It is the opinion of this author that most of
the critique of the Basket is populist. The Israeli Basket is one of the best and
most generous of its kind in the world.
174. Ellen Waldman, Cultural Priorities Revealved: The Development and
Regulation of Assisted Reproduction in the United States and Israel, 16 HEALTH
MATRIX 65, 67 (2006). ART includes fertility treatments in which both eggs and
sperm are handled in the laboratory (i.e., in vitro fertilization and related
procedures). See also, Victoria Clay Wright, et al., Assisted Reproductive
Technology Surveillance - United States, 2003, 55 MORBIDITY AND MORTALITY
WEEKLY REPORT 1 (Ctr. for Disease Control, Atlanta, Ga.), May 26, 2006,
available at http://www.cdc.gov/ mmwr/ preview/ mmwrhtml/ ss5504al.htm.
(stating that IVF treatments account for about 99% of ART procedures in the
United States).
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Professor Ellen Waldman's statement above is the result of two
diametrically opposed models of providing and financing ART.' On
the one hand is the American model. While the United States is a
world leader in ART, as in many advanced medical technologies,
7 6
ART expenses are viewed in the United States "primarily as a luxury
expenditure, the costs of which [are primarily] shouldered by fertility
consumers."'' 77  Indeed, since the 1980s the "baby business" has
developed greatly, with about 8 million infertile women in the United
States spending around $3 billion a year in order to conceive.'7 8 The
costs are high. A single IVF cycle alone is estimated to cost at least
$12,000 and the treatment as a whole may cost upwards of $70,000-
and that's before the child-rearing expenses of diapers, orthodontics,
and college tuition.179 Some women are "seeking help in places like
South Africa, Israel, Italy, Germany, and Canada, where the costs can
175. ART can be defined as "treatments or procedures which include the
handling of human oocytes or embryos, including in vitro fertilization, gamete
intrafallopian transfer, zygote intrafallopian transfer, and such other specific
technologies . . ." 42 U.S.C.A. § 263a-7(1) (2003). In vitro fertilization (IVF)
"refers to the procedure by which a woman's eggs are first extracted from her
ovaries and then fertilized outside of her body." Assessing the Viability of a
Substantive Due Process Right to In Vitro Fertilization, 118 HARV. L. REV. 2792,
2793 (2005). See generally id. (describing IVF and its status in the United States).
176. Recent data suggests that 56% of all reported ART cycles (357,884; 2003
figures) were carried out in Europe; almost 50% of the reported cycles in the
world were in four countries: USA (112,000), Germany (85,000), France (64,000),
and the UK (37,000). Press Release, European Society of Human Reproduction &
Embryology, Three Million Babies Born Using Assisted Reproductive
Technologies (Aug. 30, 2006), available at http://www.eshre.com/ emc.asp?
pageld=806 [hereinafter ESHRE]. However, research suggests there is a
significant difference in favor of the American system in relation to pregnancy
rates and live birth rates. See Norbert Gleicher, Andrea Whghofer & David
Barad, A Formal Comparison of the Practice of Assisted Reproductive
Technologies Between Europe and the USA, 21 HUMAN REPRODUCTION 1945,
1945, 1946, 1948, tab. 2, at 1947 (2006). See generally THE REGULATION OF
ASSISTED REPRODUCTIVE TECHNOLOGY (Jennifer Gunning & Helen Szoke eds.,
Ashgate Publishing, 2003) (giving a more global perspective on the issue).
177. Waldman, supra note 174, at 87.
178. David Plotz, How Making Babies has Become a $3 Billion Industry-and an
Unregulated Mess, THE WASHINGTON POST, Feb. 26, 2006, at BW05 (reviewing
DEBORAH L. SPAR, THE BABY BUSINESS: How MONEY, SCIENCE, AND POLITICS
DRIVE THE COMMERCE OF CONCEPTION (Harvard Business School Press 2006)).
179. See id.
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be much lower, becoming in essence fertility tourists."1' 8 As one expert
observed: "The fertility-industrial complex is a stunning array of
businesses-practically a microcosm of the entire global economy.. 8.
The first IVF birth took place in 1978; over twenty-five years later,
there is almost no U.S. federal regulation covering IVF and no
government support for IVF research.1 8 U.S. regulation of IVF is a
patchwork. The states that do have laws concerning IVF regulation all
vary greatly in their scope of what procedures and methods are to be
regulated. The conclusion is that state regulation, like federal
regulation, is limited.83
Israel is a stark contrast to the United States. Israel's current status
in this field is the result of heavy investment of public resources in
providing wide and free access to ART treatment as part of "the basic
package of health benefits guaranteed by the government.
'8
Additionally, IVF clinics are abundant and Israeli fertility experts are
global leaders in their fields."' This extremely pro-reproductive policy
is a result of the country's religious beliefs, grounded in the Bible's Old
186Testament. Due to IVF being in the Basket, the Israeli governmentcovers the entire cost of any and all IVF cycles for its women citizens.8
180. Felicia R. Lee, Driven By Costs, Fertility Clients Head Overseas, N.Y.
TIMES, Jan. 25, 2005, at Al.
181. Plotz, supra note 177, at BW05. Other medical costs include "sperm ($275
a vial), eggs (up to $50,000 apiece), and nine months use of a womb ($20,000)." Id.
See also Leslie Grant Timmins, Ancient Medicine for a Modern Problem, GLOBE &
MAIL, April 15, 2006, at F9 (stating IVF is expensive and doesn't always work, so
some are turning to traditional Chinese treatments such as acupuncture);
American Society of Reproductive Medicine, Frequently Asked Questions About
Infertility, http://www.asrm.org/ Patients/ faqs.html (last visited Nov. 21, 2006)
[hereinafter ASRM] ("The average cost of an IVF cycle in the United States is
$12,400.").
182. Assessing the Viability of a Substantive Due Process Right to In Vitro
Fertilization, supra note 175, at 2792. The lack of regulation can be traced to the
federal government's reluctance to fund IVF research. "In the absence of
government support, the IVF industry has developed entirely within the private
sector. This reliance on private funds explains much of the current laissez-fair
state of IVF industry regulation." Id. at 2794.
183. Id at 2795-96. See also Jennifer L. Rosato, The Children of Art (Assisted
Reproductive Technology): Should the Law Protect them from Harm?, 2004 UTAH
L. REV. 57,62-66 (2004).
184. Waldman, supra note 174, at 87.
185. See F. Simonstein, Pressures on Women to Reproduce and the Drive
Towards Assisted Reproductive Technologies, 25 MED. & L. 355, 359 (2005).
186. See id.
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Most nations are somewhere in the middle of the spectrum, between
these two models.'88 Spending public funds on ART treatments is, in
general, a difficult public policy question to handle.'8 9 On the one
hand, if a nation has limited public resources and a chronically under-
funded public healthcare system, easing the pain and suffering of the
living could be viewed as more urgent than producing the unborn., 9°
Furthermore, planning and producing a family is a very private matter,
an area where public regulation is most unwelcome. The idea of such
intervention has troubling implications.' In addition to these
Jewish women are under extraordinary pressure to reproduce, whether
they are married or not. The barren woman is an archetype of suffering in
the Israeli-Jewish mentality. From the childlessness of the matriarchs in
the book of Genesis about which every Israeli schoolchild learns from the
age of six, Israelis learn that barrenness is tragic for a woman .... Israeli
reproductive policies do not protect women but rather seem to protect the
biblical command 'be fruitful and replenish the earth' (citation omitted.).
Id. at 359, 360
187. See id. at 362.
188. Sandra Dill, Consumer Perspectives, CURRENT PRACTICES AND
CONTROVERSIES IN ASSISTED REPRODUCTION, 255, app. A at 263-71 (Effy Vayena,
et al. eds., 2002), available at http://www.who.int/ reproductive-health/ infertility/
25-2.pdf.
189. See generally Peter J. Neuman, Should Health Insurance Cover 1VF? Issues
and Options, 22 J. HEALTH POL. POL'Y & L. 1215 (1997) (discussing the value of
IVF, the emotional debate surrounding IVF, and state action in this area).
190. See e.g., Adi Bar-Lev, Just Allocation of Reproductive Choice: The Case of
Israel's Sick Funds, 00 APA NEWSLETTERS (Am. Philosophical Ass'n, Newark,
Del.), Spring 2001, available at http://www.apa.udel.edu/ apa/ publications/
newsletters/ vOOn2/ medicine/ 14.asp (giving an example that compares two
women).
One wishes to conceive a child, the other seeks to terminate her
pregnancy ... The predicaments at hand are far more similar than they
may appear. Neither woman is in grave physical jeopardy; neither
requires treatment to prolong her life. Both would suffer a decline in
perceived quality of life if denied the procedures they seek ...
[Unfortunately, with the Basket and] Israel's universal healthcare system,
the needs of only one woman would be met. The former would receive all
medical interventions modern technology has availed; the latter would
not.
Id.
191. Consider the horror with which the Chinese "one-child-per-family policy"
was met in the West, and the idea of public involvement in family planning feels
quite inappropriate. See generally, Ling Jing Zhou, Provision of Assisted
Reproductive Technology for Single Women in China: A New Challenge, 23 MED.
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concerns is the 16% of all couples worldwide who face fertility issues."'
ART is an expensive, elective treatment; success rates are only around
25-30%.193 As long as the debate is focused on the medical benefits of
ART, as it has been in England, the result can be a stand-off.
194
& L. 433 (2004) (discussing the Chinese government's modern intrusion into the
reproductive activities of its citizenry).
192. An estimated "one in six couples worldwide experience some form of
infertility problem." ESHRE, supra note 176. See also UK Only 12th in League
for Access to IVF Treatment, TELEGRAPH, June 22, 2006,
http://www.telegraph.co.uk/ news/ main.jhtml? xml=/ news/ 2006 /06 /22
/ntwinl22.xml [hereinafter: Telegraph] ("Around one in seven couples in Britain -
3.5 million people - have problems conceiving."). The Israeli Ministry of Health's
data suggests that 16% of couples in relevant ages (over 160,000 couples) cannot
have children. In about a third of cases the problem is in the man's sperm; in 45%
of cases hormonal or mechanical deficiencies of the woman are the problem. The
rest are unexplained or are suspected to have a psychological basis. See Vared
Levy-Barzilay, Bring Six, Bring Seven, Bring Eight Children, HA'ARETZ (Isr.), Jan.
28, 2005, available at http://www.haaretz.co.il/ hasite/ pages/ ShArtPE.jhtml?
itemNo =531823 (article in Hebrew).
193. It has been asserted that, world-wide, "[t]he average pregnancy rate for
each cycle using fresh embryos was 25.1% and the delivery rate was 18.5%.
However, these rates varied from 13.6% to 40.5% for pregnancy, and 9.1% to
37.1% for delivery." ESHRE, supra note 176. In Australia, the 2003 success rates
varied from 13.9% (for frozen oocytes) to 18.6% (for fresh oocytes). JENNIFER L.
SMITH, AUSTL. HEALTH POL'Y INST., MEDICARE AND ASSISTED REPRODUCTIVE
TECHNOLOGIES, 3 (2006), http://www.ahpi.health.usyd.edu.au/ research/ publish/
ivfbrief.pdf [hereinafter SMITH, MEDICARE]. In Britain, "[n]early 30% of
treatment cycles lead to pregnancy." Ian Sample, Britan Given Low Rating on
Access to IVF Treatment, THE GUARDIAN (U.K.), June 22, 2006,
http://www.guardian.co.uk/ medicine/ story/ 0,,1803105,00.html. See also ASRM,
supra note 181 ("The average live delivery rate [in the United States] for IVF in
2000 was 29.9 per cent per retrieval."). All of these figures raise an interesting
public policy question: is a 25-30% success rate the sign of a highly developed and
productive technique, or a highly wasteful and not very pleasant medical
procedure?
194. See Mark Henderson, Junk Medicine: IVF Treatment, THE TIMES (U.K.),
June 24, 2006, http://www.timesonline.co.uk/ article/ 0,,8123- 2238654,00.html
[hereinafter Henderson, Junk Medicine] (describing the debate amongst doctors
and administrators, some of who argue that "it is inappropriate for the state to pay
for treatment of a disorder that threatens no lives. Others, including most
gynecologists and patient groups, [take the other side and] regard infertility as an
organic and deeply distressing illness no less deserving of free therapy than any
other.").
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Recent studies suggest that it makes sound economic sense for the
government to sponsor ART treatments. Professor William Ledger of
Britain's University of Sheffield estimates that every baby born in
Britain through "[National Health Service] IVF treatment carrie[d] a
price-tag of £13,000 . . . [but even after her] education, child benefit
and healthcare are paid for, [she] will contribute, on average, a net
£147,138 to the Exchequer throughout [her] lifetime."'95 Ledger and
his team argue that "the data gives weight to the argument that the
NHS should fund three cycles of IVF, as clinicians recommend . . .
[resulting] in 10,000 more IVF babies over two to three years."'96 In
order to provide context, "[t]he NHS currently spends £85 million on
providing a single cycle of IVF to women under 40. It would cost
about £100 million more to offer three free cycles."'' 97 Thus, by
properly funding IVF births, the British government can contribute
over £45,000 to the country's revenue.
Additionally, the research suggests that IVF treatments could also
help address another major problem facing Western nations, the
demographic problem of an aging population. EU total fertility rates
(TFR) are now below replacement levels.'98 Replacement levels are
usually gauged to be at 2.1 children per woman; however, European
averages for some countries have fallen below 1.5 children per
woman. 1 A RAND Europe report on ART suggests that the
combination of increased life expectancy and declining fertility will
lead to a doubling of the proportion of the population over sixty-five to
30% by 2050.200 This would create a greater burden on the working
class to provide for the growing number of pensioners.20' The RAND
195. Id. ("[She] pays for itself by the age of 31 in tax alone: the model does not
include the wealth it creates in the private sector. The "break-even" point is just
two years older than for naturally conceived children, who contribute a net
o160,069.").
196. Caroline Ryan, IVF 'Good for British Economy', BBC NEWS, June 19,
2006, http://news.bbc.co.uk/ 1/hi/ health/ 5095884.stm.
197. Mark Henderson, Multiple Births from JVF are 'Dangerous and Costly',
THE TIMES (U.K.), June 23, 2005, http://www.timesonline.co.uk/ article/ 0,,8122-
1665206,00.html [hereinafter: Henderson, Multiple Births].
198. JONATHAN GRANT, ET AL., RAND EUROPE, SHOULD ART BE PART OF A
POPULATION POLICY Mix? 8 (2006), available at http://www.rand.org/ pubs/
documented- briefings/ 2006/RAND_ DB507.sum.pdf #search= %22Jonathan
%20Grant %20RAND %20Europe %20IVF %22.
199. Id.
200. Id. at 1.
201. Id.
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study suggests that even small increases in the number of ART cycles
provided would amount to an extra 20,000 babies being born per
year.2 The study suggested that increased ART is more cost effective
than other methods that may be available to a government.
2°3
B. Israel in a Comparative Perspective
Israel is the clear leader in the availability of IVF treatment, even
when compared to the leading European welfare states. 204  As a
comparison, the British healthcare trusts are required by law to
provide one free cycle of IVF to patients.05 Yet these health trusts,
through their internal policies, have been avoiding this government
mandate and not providing the free cycles. 206 Alternatively, Danish
public health services offer five free cycles of PVE. 207 Australia is the
most similar to Israel in funding IVF in that both countries are the only
two to offer public funding for ART that is not capped.""
Israel's IVF policy is such that "[p]ublicly-funded IVF is provided
practically without limitations, for a wide range of indications, with
minimal payment at the point of delivery. Women of all ages, marital
202. Id. at 2.
203. See id.
Including ART in a population policy mix may even be more cost-
effective than other measures. A comparison of cost per additional birth
showed that whereas a 25% increase in child benefits would raise TFR by
0.07, the cost per additional birth was between £50,000 and £100,000. The
average cost per additional ART birth was estimated at £15,000-£25,000.
Id. at 8. See also Guy Laroque & Bernard Selani6, Does Fertility Respond to
Financial Incentives?, Ctr. For Econ. Pol'y Research, Discussion Paper (2004)
available at http://papers.ssrn.com/sol3/papers.cfm ?abstractid=772706.
204. Kristy Horsey, Three Million IVF Babies Born Worldwide, BIONEWS
(U.K.), June 28, 2006, http://www.bionews.org.uk/ new.lasso? storyid=3086
("Availability was found to be at its highest in Israel, which gave 3,260 cycles per
million population, followed by Denmark, at 2,031 cycles per million.").
205. Henderson, Multiple Births, supra note 197. Further, this funding is only
for women under 40. Id.
206. See Severin Carrell & Steve Bloomfield, The Fertility Gap, THE
INDEPENDENT (U.K.), Feb. 9, 2007 available at http://news.independent.co.uk/ uk/
health_ medical/ article356652.ece.
207. Sample, Britan Given Low Rating on Access to JVF Treatment, supra note
193.
208. SMITH, MEDICARE, supra 193, at 3.
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status and sexual preference are entitled to treatment, until they have
two children from the present relationships. '"" 9
The reasons for the unique Israeli position have been well explored,
and they mostly relate to Israel's cultural context. Across Jewish-
Israeli class and ethnic lines great emphasis is placed on the creation
and preservation of a family, elevating child-bearing to one of life's
central tasks. Both Jewish men and women are subject to societal
pressures to reproduce. The Jewish man is commanded to procreate
according to tradition and the archetype of the barren woman is the
Jewish epitome of failed purpose . °
The Israeli policy is not without critics. While the Israeli system
legitimates women's reproductive ambitions through the moral and
financial support of the state, critics of the Israeli system note that it
turns private procreative matters into "public works projects." 21
Other criticisms see the Israeli program simply as a means of• - 212
implementing a Biblical imperative, or even a way of constitutionally
mandating motherhood to those who would otherwise not opt to have
children.2 There is also criticism of gynecologists' eagerness to have
couples undergo fertility treatments, although 85% of the young
couples will conceive naturally within a year, and 93% within two
214years.
Finally, it must be noted that some efforts to cap the availability of
IVF treatments have been made over the years. Public outrage
developed during an initiative in the 1990's to limit state coverage to
209. Daphna Birenbaum-Carmeli, 'Cheaper Than a Newcomer': on the Social
Production of IVF Policy in Israel, 26 SOC. OF HEALTH & ILLNESS 897, 900 (2004)
(citations omitted).
210. See Waldman, supra 174, at 70. See also Frida Simonstein, Pressures on
Women to Reproduce and the Drive Towards Assisted Reproductive Technologies,
25 MED. & L. 355, 359 (2006); Miryam Z. Wahrman, Fruit of the Womb: Artificial
Reproductive Technologies & Jewish Law, 9 J. GENDER RACE & JUST. 109,
109-12 (2005) (discussing Jewish cultural attitudes toward reproduction).
211. Waldman, supra 174, at 87.
212. Simonstein, supra note 210, at 360.
213. Birenbaum-Carmeli, supra note 209, at 902.
214. See Vered Levy-Barzilay, Bring Six, Bring Seven, Bring Eight Children,
supra note 192.
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seven cycles of IVF.215  In addition, the public has expressed
resentment to small monthly co-payments.2
16
CONCLUSION
Between the years 1903 and 1904, Austrian composer Gustav
Mahler wrote a song cycle for voice and orchestra titled
Kindertotenlieder, or Songs of the Death of Children.2" Around this
period, he became the father of two beautiful, healthy daughters.2 8
Yet in 1907, Mahler's daughter, Maria, died of either scarlet fever or
diphtheria at the age of four.219 Some describe Mahler's obsession with
death as prescient . 2  It is fair to suggest he was merely a concerned
215. See Birenbaum-Carmeli, supra note 209, at 907-08.
216. Nirit Shapira, How Much Does a Baby Cost?, HA'ARETZ (Isr.), Mar. 30,
1998, available at http://www.haaretz.co.il/ arch (article available in Hebrew via
subscription).




220. As part of the "Mahler Cult" that evolved in the late 2 0 h century, many
compositions of his last years, especially the Kindertotenlieder and the Sixth and
Ninth Symphonies, came to be interpreted as emotionally foreshadowing of both
Mahler's personal-life tragedies and the 20th century tragedies that brought about
the destruction of the world-order Mahler knew. Within a few years after his
death, the first World War brought down the Austro-Hungarian empire. Later,
the Second World War brought additional destruction, especially to Europe's
Jewry. Mahler's artistic premonition remains a fascinating issue. See generally
Vera Micznik, The Farewell Story of Mahler's Ninth Symphony, 20 19TH-CENTURY
Music 144 (1996) (discussing how the composer's Nonth Symphony was a
narrative of his farewell to the world and life); STEINBERG, supra note 217, at 313-
314 (Mahler's wife Alma was troubled by her husband's interest with the deaths of
children, and perhaps felt that he had "tempted providence by composing those
songs. Mahler himself saw it differently. He was convinced that an artist has the
power to intuit, even to experience, events before they occur."); Stuart Feder,
Mahler, Mourning and Consolation, 4 NATURLAUT 8 (2005) available at
http://mahlerarchives.net/ archives/ symp.html.
What lurked perennially was death and its accoutrements-the trappings,
associations and implications of death. This was the unsettling "force"
that had touched Mahler at the seance; but he was no stranger to it.
Indeed, it might be said that Mahler had a romance with death, which is
represented richly in his music from his earliest works.
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father, and justly so."' A mere century ago, medicine had precious
little to offer for those in Mahler's position. At the beginning of the
twentieth century both the rich and poor suffered and died in much the
same way as Mahler's daughter; often from inflictions that have been
completely eradicated or minimized today. Consider that "[i]n 1900 in
some U.S. cities, up to 30% of infants died before reaching their first
birthday.2 2 12  From 1915 through 1997, the infant mortality rate
declined in the United States so dramatically, that the Center for
Disease Control proudly noted that "[t]he decline in infant mortality is
unparalleled by other mortality reduction this century.,
223
These statistics give hope for expanding families. They may find
comfort in the achievements of American public health, social welfare,
and clinical medicine (both pediatrics and obstetrics). These
improvements may relieve them of their worst fears for expectant-
Id. at 8. But see Richard Bernstein, Reality Check for the Mythic Mahler, N.Y.
TIMES, Jan. 21, 1998, at E9 ("Jonathan Carr [in Mahler: A Biography]... finds little
to indicate that Mahler's life was burdened by a sense of impending catastrophe.").
221. Mahler was "an expert on the deaths of children," having lost relatives at
various ages. STEINBERG, supra note 159, at 274. See also Nicky Hart, Beyond
Infant Mortality: Gender and Stillbirth in Reproductive Mortality Before the
Twentieth Century, 52 POPULATION STUDIEs 215,226 (1998).
It is worth reminding ourselves that the national infant mortality rate of
nations like Russia or Austria was in the region of 300 per 1,000 live births
(excluding stillbirths) in the first decade of [the 20"] century. This level of
reproductive mortality seems fantastic today but in some parts of Europe
it was routine in the early twentieth century.
Id. at 226.
222. Assisted Reproductive Technology Surveillance United States, 2003, 48
MORBIDITY AND MORTALITY WEEKLY REPORT (Ctr. for Disease Control, Atlanta,
Ga.), Oct. 1, 1999 available at www.cdc.gov/ mmwr/ preview/ mmwrhtml/
mm4838a2.htm.
223. Id.
At the beginning of the 20th century, for every 1000 live births, six to nine
women in the United States died of pregnancy-related complications, and
approximately 100 infants died before age 1 year(1,2) . . . From 1915
through 1997, the maternal mortality rate declined almost 99% to less
than 0.1 reported death per 1000 live births (7.7 deaths per 100,000 live
births in 1997) ...
Id. See also Chicago Public Library, 19th and 20th Century: Infant and Childhood
Mortality www.chipublib.org/ 004chicago/ disasters/ infant- mortality.html (last
visited Oct. 21, 2006) ("In 1870, with 4,000 deaths in the 0-4 age group, a Chicago
child had a 50% chance of reaching the age 5.").
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mothers and children.2  Unfortunately, the blessings of modern
medical research and treatment literally come at a price. As this price
consistently rises faster than economic growth, it is clear that in coming
years we shall increasingly face tough financial dilemmas. Seeking the
most advanced medical treatment may require cuts in other
expenditures.
These dilemmas must be faced at various levels: that of the
individual, that of nations, and that of the international community.
This article only deals with the middle of the three. It seems safe to
assume that well-to-do individuals will keep seeking top-notch medical
treatment, whatever the cost, and that medical research and
development will continue rolling-out sophisticated and expensive
medical procedures, treatments, and medications. On the
international level it seems fair to say that this current difference in the
availability of medical care between the world's richer and poorer
nations is already unacceptable. Further advances in Western
medicine are likely to widen the gap, but this seems almost irrelevant
given the existing disparity.
221
This article addresses some of the dilemmas raised at the national
level, such as how a national government is to deal with the rising costs
224. The reduction in infant mortality occurred among all Western nations, but
the rates among the world's less developed and poorer nations is alarmingly high.
See generally U.N. DEVELOPMENT PROGRAMME, Human Development Report:
Goal 4 Reduce Child Mortality (2003), available at http://hdr.undp.org/ reports/
global] 2003! indicator/ pdf/ hdr03_tableMDG3.pdf (giving relevant data for all
major nations). See also ORG. FOR ECON. CO-OPERATION AND DEV., OECD
HEALTH DATA 2005 How DOES THE UNITED STATES COMPARE 2(2005),
http://www.oecd.org/ dataoecd/ 15!23/ 34970246.pdf ("Infant mortality rates in the
United States have fallen greatly over the past few decades, but not as much as in
most other OECD countries... Among OECD countries, infant mortality is the
lowest in Japan and the Nordic countries . all below 3.5 deaths per 1 000 live
births.").
225. To use the earlier example of infant mortality: UN 2003 figures suggest
that US figures (7 deaths per 1,000 live births) are about eight times better than
the world average (56 deaths per 1000 live births), twelve times better than
Pakistan (84 deaths per 1,000 live births), and over twenty-three times better than
Afghanistan (165 deaths per 1,000 live births). U.N. DEVELOPMENT PROGRAMME,
supra note 224, at 208-212. See e.g. World Health Organization, Health
Inequalities, http://www.who.int/ health-systems- performance/ docs/
healthinequality_ docs.htm (last visited Nov. 21, 2006); Economic and Social
Research Council, ESRC Society Today Global Health Inequalities,
http://www.esrc.ac.uk/ ESRCInfoCentre/ facts/ international/ health.aspx?
Componentld= 14902 &SourcePageld- 14912 (last visited Nov. 21, 2006).
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and growing needs for medical care within its budget. This paper
presents two aspects of the Israeli experience. The Israeli government
is committed to the provision of a "healthcare basket" of medical
services to its entire population. The government has formed a
professional advisory committee to recommend how to annually
update the Basket. The government's chronic under-funding of this
Committee resulted in the Committee adopting a policy clearly
preferring the purchase of expensive new drugs to treat small numbers
of severely ill patients, rather than advancing policies that would
improve the public health of a greater number of people. Mounting
public, political, medical-professional, and ethical pressures on the
Committee led the government back to the administrative drawing
board.
The final chapter of this article presented a unique Israeli public-
health-policy decision: to provide almost unlimited funding for fertility
treatments. For cultural and religious reasons, the Israeli polity has
coalesced around two types of patients who have first priority and
receive treatment almost irrespective of cost; all other patient
categories then stand in line. The Israeli experience should be of
interest and possibly of use to other national governments when setting
their priorities in allocating public money for healthcare treatment.
2006]
